Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2010/059426
International filing date: 08 December 2010 (08.12.2010)

Document type: Certified copy of priority document
Document details: Country/Office: US
Number: 61/267,645
Filing date: 08 December 2009 (08.12.2009)

Date of receipt at the International Bureau: 16 December 2010 (16.12.2010)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a),(b) or (b-bis)
THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

December 15, 2010

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 61/267,645
FILING DATE: December 08, 2009
RELATED PCT APPLICATION NUMBER: PCT/US10/59426

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS US61/267,645

Certified by

[Signature]

Under Secretary of Commerce
for Intellectual Property
and Director of the United States Patent and Trademark Office
## INVENTOR(S)

<table>
<thead>
<tr>
<th>Given Name (first and middle [if any])</th>
<th>Family Name or Surname</th>
<th>Residence (City and either State or Foreign Country)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRZYSZTOF</td>
<td>PALCZEWSKI</td>
<td>BAY VILLAGE, OH</td>
</tr>
<tr>
<td>AKIKO</td>
<td>MAEDA</td>
<td>MAYFIELD HEIGHTS, OHIO</td>
</tr>
<tr>
<td>MARCIN</td>
<td>GOLCZAK</td>
<td>MAYFIELD HEIGHTS, OHIO</td>
</tr>
</tbody>
</table>

Additional inventors are being named on [separately numbered sheets attached here.]

## TITLE OF THE INVENTION (500 characters max):  
METHOD OF TREATING OCULAR DISORDERS

Direct all correspondence to:  

<table>
<thead>
<tr>
<th>CORRESPONDENCE ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>The address corresponding to Customer Number: 68,705</td>
</tr>
</tbody>
</table>

OR  
[ □ ] Firm or Individual Name

Address:

City:  
State:  
Zip:  
Country:  
Telephone:  
Email:

## ENCLOSED APPLICATION PARTS (check all that apply)

- Application Data Sheet. See 37 CFR 1.76
- CD(s), Number of CDs
- Drawing(s) Number of Sheets 9
- Other (specify)
- Specification (e.g. description of the invention) Number of Pages 104

Fees Due: Filing Fee of $220 ($110 for small entity). If the specification and drawings exceed 100 sheets of paper, an application size fee is also due, which is $270 ($135 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

## METHOD OF PAYMENT OF THE FILING FEE AND APPLICATION SIZE FEE FOR THIS PROVISIONAL APPLICATION FOR PATENT

[ □ ] Applicant claims small entity status. See 37 CFR 1.27.  
[ □ ] A check or money order made payable to the Director of the United States Patent and Trademark Office is enclosed to cover the filing fee and application size fee (if applicable).

<table>
<thead>
<tr>
<th>Method of Payment</th>
<th>Total Fee Amount ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Payment by credit card. Form PTO-2038 is attached.</td>
<td>$110.00</td>
</tr>
<tr>
<td>The Director is hereby authorized to charge the filing fee and application size fee (if applicable) or credit any overpayment to Deposit Account Number: 20-0090</td>
<td></td>
</tr>
</tbody>
</table>

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☐ No.
☒ Yes, the name of the U.S. Government agency and the Government contract number are: EY09339

NATIONAL INSTITUTE OF HEALTH

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

SIGNATURE /Richard A. Sutkus/ Date 8 December 2009

TYPED or PRINTED NAME Richard A. Sutkus REGISTRATION NO. 43,941
(if appropriate)

TELEPHONE 216.621.2234 Docket Number: CWR-019171US PRO
METHOD OF TREATING OCULAR DISORDERS

TECHNICAL FIELD

The present invention relates to a method of treating ocular and/or retinal disorders that are associated with aberrant all-trans-retinal clearance in the retina, and more particularly to methods and compounds of treating retinal degeneration and/or retinal disorders using primary amine compounds.

BACKGROUND OF THE INVENTION

Human visual perception is an essential sense that reflects genetic background, withstands many environmental insults and deteriorates with age. With respect to molecular investigations, this field can be divided into phototransduction, which deals with propagation of the light signal, and the visual (retinoid) cycle, consisting of metabolic pathways that regenerate the chromophore. But in reality these two pathways are fully integrated and complementary.

Rhodopsin in rod photoreceptors and cone opsins in cone photoreceptors respond to light. Their common chromophore, 11-cis-retinal (actually 11-cis-retinylidene in the bound form), is covalently linked via a protonated Schiff base to polypeptide chains embedded within the transmembrane domain of each opsin. Upon absorption of a photon, the chromophore undergoes photoisomerization to all-trans-retinylidene, changing the opsin from an inactive to active conformation. This active form, known as Meta II, then recruits and binds intracellular G proteins, continuing the visual signal cascade that culminates in an electrical impulse to the brain.

The retinoid (visual) cycle is a complex enzymatic pathway essential for regeneration of the visual chromophore, 11-cis-retinal, a component of rhodopsin and cone opsins that undergoes activation by light in vertebrate eyes. Maintaining continuous vision and preserving the health of photoreceptors requires an adequate continuing supply of this aldehyde so vertebrates evolved the retinoid cycle to achieve this objective. The pathway operates in both photoreceptor cells and the retinal pigmented epithelium (RPE), converting all-trans-retinal back to 11-cis-retinal by several chemical transformations. Whereas the classical vertebrate retinoid cycle contributes primarily to regeneration of rhodopsin in rod cells, RPE65-based chromophore production may also be important for cone function.
Inadequate availability and/or processing of vitamin A to the visual chromophore, 11-cis-retinal can adversely affect vertebrate rhodopsin regeneration and visual congenital or progressive blindness in humans. Inactivation of non-redundant enzymes of the retinoid cycle, e.g., either LRAT that esterifies all-trans-retinol or the retinoid isomerase called RPE65, produces Leber congenital amaurosis (LCA), a leading cause of inherited childhood blindness. LCA is an autosomal recessive, early onset severe retinal dystrophy that accounts for 5% of all inherited retinal dystrophies. Insufficient vitamin A in the diet also can lead to progressive deterioration of vision and ultimately blindness, a major problem in underdeveloped countries.

Whereas inadequate 11-cis-retinal production leads to congenital blindness in humans, accumulation of the photoisomerized chromophore all-trans-retinal also can be detrimental. Such is the case when this reactive aldehyde is not efficiently cleared from the internal membranes of retinal outer segment discs. Clearance of all-trans-retinal involves two steps: 1). Translocation of all-trans-retinal across the photoreceptor disc membranes by ATP-binding cassette transporter 4 (ABCA4), and 2). Reduction of all-trans-retinal to all-trans-retinol by retinol dehydrogenase 8 (RDH8), expressed in the outer segments of photoreceptors, and by RDH12 located in photoreceptor inner segments.

ABCA4, also known as ABCR or the rim protein, localizes to the rim of photoreceptor discs and transfers all-trans-retinal from the inside to the outside of disc membranes after it is released from visual pigments. Mutations in ABCA4 can cause Stargardt macular degeneration, cone-rod dystrophy, or recessive RP. Also, heterozygous mutations in ABCA4 increase the risk of developing age-related macular degeneration. Di-retinoid-pyridinium-retinylethanamine (A2E) and retinal dimer (RALdi) conjugates are the major fluorophores of lipofuscins produced from all-trans-retinal. Even in the presence of a functional transporter, both A2E and RALdi can accumulate as a consequence of aging together with light exposure and produce toxic effects on RPE cells. Patients affected by age-related macular degeneration, Stargardt disease with a disabled ABCA4 gene or other retinal diseases associated with lipofuscin accumulation develop retinal degeneration. ABCA4 mutations also are linked to a high risk of AMD.
SUMMARY OF THE INVENTION

[0008] The present invention relates to a method of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina. The ocular disorder can include, for example, retinal disorders, such as retinal degeneration, macular degeneration, including age-related macular degeneration, Stargardt disease, and retinitis pigmentosa. The method includes administering to the subject a therapeutically effective amount of a primary amine compound of formula:

\[ R_1 \text{NH}_2 \]

wherein \( R_1 \) is an aliphatic and/or aromatic compound. The primary amine compound upon administration to the subject forms a reversible Schiff-base with the all-trans-retinal without adversely affecting normal retinoid cycle performance. The primary amine compound when administered to a \( Rdh8^{-}Abca4^{-} \) mouse increases the optical coherence tomography score of the mouse, which reflects severity in retinal morphology, to at least about 2.5 and increases 11-cis-retinal amount at least about 30% in comparison to untreated control animal. The primary amine compound is not a local anesthetic, which includes an aromatic amine that demonstrates sodium channel blockade when administered to the subject.

[0009] In an aspect of the invention, the primary amine compound does not inhibit RPE65 enzymatic activity or any other proteins involved in retinoid metabolism in the eye of the subject.

[0010] The primary amine compounds can reduce the formation of A2E and/or retinal dimer in the subject’s retina and promote 11-cis-retinal production in the subject. The primary amine compound does not inhibit night blindness.

[0011] In another aspect of the invention, the primary amine compound can be delivered to the subject by at least one of topical administration, systemic administration, intravitreal injection, and intraocular delivery. In one example, the primary amine can be provided in an ocular preparation for sustained delivery.

[0012] In a further aspect of the invention, \( R_1 \) is an aliphatic compound or an aromatic compound. In another aspect, the primary amine compound can include at least one compound of the formula:
wherein $R_2$ is hydrogen or (C$_1$-C$_6$) straight chain or branched unsubstituted or substituted alkyl;

$R_3$ is straight or branched unsubstituted or substituted alkyl of from 1 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl, OH, -alkylphenyl, -alkylphenoxy, -phenyl or substituted phenyl;

$R_4$ is hydrogen or (C$_1$-C$_6$) straight chain or branched unsubstituted or substituted alkyl, or carboxyl;

$Ar$ is phenyl, which is unsubstituted or substituted with 1-5 of $R_7$, wherein $R_7$ is independently selected from the group consisting of:

1. halogen,
2. C$_{1-6}$ alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens,
3. OC$_{1-6}$ alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens, and
4. CN;

$X_1$ is selected from the group consisting of:

1. N, and
2. CR$_6$;

$R_5$ and $R_6$ are independently selected from the group consisting of:

1. hydrogen,
2. CN,
(3) C_{1-10} alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 halogens or phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R_8, OR_8, NHSO_2 R_8, SO_2 R_8, CO_2 H, and CO_2 C_{1-6} alkyl, wherein the CO_2 C_{1-6} alkyl is linear or branched,

(4) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R_8, OR_8, NHSO_2 R_8, SO_2 R_8, CO_2 H, and CO_2 C_{1-6} alkyl, wherein the CO_2 C_{1-6} alkyl is linear or branched, and

(5) a 5- or 6-membered heterocycle which may be saturated or unsaturated comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being unsubstituted or substituted with 1-3 substituents independently selected from oxo, OH, halogen, C_{1-6} alkyl, and OC_{1-6} alkyl, wherein the C_{1-6} alkyl and OC_{1-6} alkyl are linear or branched and optionally substituted with 1-5 halogens;

R_8 is C_{1-6} alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 groups independently selected from halogen, CO_2 H, and CO_2 C_{1-6} alkyl, wherein the CO_2 C_{1-6} alkyl is linear or branched;

R_9 and R_{10} may be the same or different and are hydrogen, straight or branched alkyl of from one to six carbon atoms, lower alkylaryl, lower alkenyl, phenyl, CF_3, hydroxy, lower alkoxy, lower alkylthio, lower alkylsulphonyl, CF_3 O, at the six position halogen, nitro, carboxy, lower alkoxy carbonyl, NR_{11}R_{12} CO, NR_{11}R_{12}, R_{11}CONR_{12}, CN, NR_{11}R_{12}SO_2, wherein R_{11} and R_{12} may be the same or different and are hydrogen, lower alkyl, or aryl; R_9 and R_{10} may together form a carbocyclic or methylenedioxy ring;

R_{14} is cyano, cyanomethyl, methoxymethyl, or ethoxymethyl;

X_2 is O, N(H), or S, het is a 5 or 6-membered heterocycle, n is 0, 1, 2, or 3, and each D is an unbranched lower alkyl group;

U is a substituent selected from halogen atom; cyano; lower alkyl wherein one or more hydrogen atoms on the lower alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms; lower alkylthio wherein one or more hydrogen atoms on the alkyl group are
optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl; lower alkylsulfonyl wherein one or more hydrogen atoms on the alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxy carbonyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylaminocarbonyl; amino; N-lower alkylamino; N,N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino)sulfonylamino; (N,N-di-lower alkylamino)sulfonylamino; aryl, optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, aryl and amino; and a monocyclic or bicyclic heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms;

W, X, Y, and Z are each, independently, N, S, O, CU or CH, such that at least one of W, X, Y, and Z is N;

A is

\[\text{D is unbranched lower alkyl;}
\]
\[\text{R}_{15} \text{ and } \text{R}_{16} \text{ are each independently substituted or unsubstituted C}_1 \text{, C}_2 \text{, C}_3 \text{, C}_4 \text{, C}_5 \text{, C}_6 \text{, C}_7 \text{, or C}_8 \text{, straight chain alkyl, or substituted or unsubstituted C}_3 \text{, C}_4 \text{, C}_5 \text{, C}_6 \text{, C}_7 \text{, or C}_8 \text{, branched chain alkyl;}
\]
\[\text{L is a single bond or CH}_2 \text{;}
\]
\[\text{m is 0, 1, or 2;}
\]
\[\text{n is 0, 1, 2, 3, or 4;}
\]
\[\text{Y}_1 \text{ is } \text{--(CH)}_{2j} \text{--, or --(CH)}_{3j} \text{--;}
\]
\[\text{--CH}_2 \text{CH(} \text{CH}_3 \text{) or --CH}_2 \text{C(} \text{CH}_3 \text{)2--;}
\]
\[\text{R}_{17} \text{ is aryl or heteroaryl;}
\]
\[\text{R}_{18} \text{ and } \text{R}_{19} \text{ are each independently C}_1 \text{-C}_4 \text{ alkyl or 2-methoxyethyl;}
\]
\[\text{R}_{20} \text{ is hydrogen, C}_1 \text{-C}_4 \text{ alkyl, 2-(C}_1 \text{-C}_4 \text{ alkoxy)ethyl, cyclopropylmethyl, benzyl, or --(CH)}_{2m} \text{COR}_{21} \text{ where m is 1, 2 or 3 and R}_{21} \text{ is hydroxy, C}_1 \text{-C}_4 \text{ alkoxy or --NR}_{22} \text{ where R}_{22} \text{ is hydrogen or C}_1 \text{-C}_4 \text{ alkyl;}
\]
R_{23} and R_{24} can be the same or different and are hydrogen, methyl, or ethyl as well as pharmaceutically acceptable salts thereof.

In a further aspect of the invention, the primary amine compound can be selected from the group consisting of:

\[ \text{Chemical Structures} \]

- A molecule with a cyclohexane ring and an amino group
- A molecule with two phenyl rings and a sulfonic acid group
- A molecule with a benzene ring and a carboxylic acid group
- A molecule with a benzene ring and an amide group

and pharmaceutically acceptable salts thereof.

[0014] In a still further aspect of the invention, the primary amine compound can be selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Fig. 1 is a schematic illustration of the visual cycle.
[0016] Fig. 2 is a schematic illustration of retinoid flow and all-trans-retinal clearance in the visual cycle.
[0017] Fig. 3A-B illustrates UV/Vis spectra for active and inactive primary amine compounds in accordance with an aspect of the invention.
[0018] Fig. 4A-B illustrates UV/Vis spectra for active and inactive primary amine compounds in accordance with an aspect of the invention.
[0019] Fig. 5 illustrates UV/Vis spectra for an active primary amine compound in accordance with an aspect of the invention.
[0020] Fig. 6 illustrates a chromatogram of HPLC separation of retinoids.
[0021] Fig. 7 illustrates a MS/MS spectrum of ritinyl imine fragments in eyes of mice.
[0022] Fig. 8 illustrates SD-OCT images of retinas from WT and Rdh8A Abca4 mice.
[0023] Fig. 9 illustrates OCT images showing grading of retinas.

DETAILED DESCRIPTION

[0024] For convenience, certain terms employed in the specification, examples, and appended claims are collected here. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0025] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0026] The terms "comprise," "comprising," "include," "including," "have," and "having" are used in the inclusive, open sense, meaning that additional elements may be included. The terms "such as", "e.g.", as used herein are non-limiting and are for illustrative purposes only. "Including" and "including but not limited to" are used interchangeably.

[0027] The term "or" as used herein should be understood to mean "and/or", unless the context clearly indicates otherwise.
In the present specification, the structural formula of the compound represents a certain isomer for convenience in some cases, but the present invention includes all isomers such as geometrical isomer, optical isomer based on an asymmetrical carbon, stereoisomer, tautomer and the like which occur structurally and an isomer mixture and is not limited to the description of the formula for convenience, and may be any one of isomer or a mixture. Therefore, an asymmetrical carbon atom may be present in the molecule and an optically active compound and a racemic compound may be present in the present compound, but the present invention is not limited to them and includes any one. In addition, a crystal polymorphism may be present but is not limiting, but any crystal form may be single or a crystal form mixture, or an anhydride or hydrate. Further, so-called metabolite which is produced by degradation of the present compound in vivo is included in the scope of the present invention.

It will be noted that the structure of some of the compounds of the invention include asymmetric (chiral) carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry are included within the scope of the invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. The compounds of this invention may exist in stereoisomeric form, therefore can be produced as individual stereoisomers or as mixtures.

"Isomerism" means compounds that have identical molecular formulae but that differ in the nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereoisomers", and stereoisomers that are non-superimposable mirror images are termed "enantiomers", or sometimes optical isomers. A carbon atom bonded to four nonidentical substituents is termed a "chiral center".

"Chiral isomer" means a compound with at least one chiral center. It has two enantiomeric forms of opposite chirality and may exist either as an individual enantiomer or as a mixture of enantiomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a "racemic mixture". A compound that has more than one chiral center has 2n-1 enantiomeric pairs, where n is the number of chiral centers. Compounds with
more than one chiral center may exist as either an individual diastereomer or as a mixture of diastereomers, termed a "diastereomeric mixture". When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J., Chem. Educ. 1964, 41, 116).

"Geometric Isomers" means the diastereomers that owe their existence to hindered rotation about double bonds. These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.

Further, the structures and other compounds discussed in this application include all atropic isomers thereof. "Atropic isomers" are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques, it has been possible to separate mixtures of two atropic isomers in select cases.

The terms "crystal polymorphs" or "polymorphs" or "crystal forms" means crystal structures in which a compound (or salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms usually have different X-ray diffraction patterns, infrared spectral, melting points, density hardness, crystal shape, optical and electrical properties, stability and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Crystal polymorphs of the compounds can be prepared by crystallization under different conditions.

Additionally, the compounds of the present invention, for example, the salts of the compounds, can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with
other solvent molecules. Nonlimiting examples of hydrates include monohydrates, dihydrates, etc. Nonlimiting examples of solvates include ethanol solvates, acetone solvates, etc.

"Solvates" means solvent addition forms that contain either stoichiometric or nonstoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water retains its molecular state as \( \text{H}_2\text{O} \), such combination being able to form one or more hydrate.

"Tautomers" refers to compounds whose structures differ markedly in arrangement of atoms, but which exist in easy and rapid equilibrium. It is to be understood that compounds of Formula I may be depicted as different tautomers. It should also be understood that when compounds have tautomeric forms, all tautomeric forms are intended to be within the scope of the invention, and the naming of the compounds does not exclude any tautomer form.

Some compounds of the present invention can exist in a tautomeric form, which are also intended to be encompassed within the scope of the present invention.

The compounds, salts and prodrugs of the present invention can exist in several tautomeric forms, including the enol and imine form, and the keto and enamine form and geometric isomers and mixtures thereof. All such tautomeric forms are included within the scope of the present invention. Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer predominates. Even though one tautomer may be described, the present invention includes all tautomers of the present compounds. A tautomer is one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another. This reaction results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that are interconvertable by tautomerizations is called tautomerism.
Of the various types of tautomerism that are possible, two are commonly observed. In keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs. Ring-chain tautomericism, is exhibited by glucose. It arises as a result of the aldehyde group (\(-\text{CHO}\)) in a sugar chain molecule reacting with one of the hydroxy groups (\(-\text{OH}\)) in the same molecule to give it a cyclic (ring-shaped) form.

Tautomerizations are catalyzed by: Base: 1. deprotonation; 2. formation of a delocalized anion (e.g. an enolate); 3. protonation at a different position of the anion; Acid: 1. protonation; 2. formation of a delocalized cation; 3. deprotonation at a different position adjacent to the cation.

As used herein, the term "analog" refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group). Thus, an analog is a compound that is similar or comparable in function and appearance, but not in structure or origin to the reference compound.

As defined herein, the term "derivative", refers to compounds that have a common core structure, and are substituted with various groups as described herein. For example, all of the compounds represented by formula I are indole derivatives, and have formula I as a common core.

The term "bioisostere" refers to a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms. The objective of a bioisosteric replacement is to create a new compound with similar biological properties to the parent compound. The bioisosteric replacement may be physicochemically or topologically based. Examples of carboxylic acid bioisosteres include acyl sulfonimides, tetrazoles, sulfonates, and phosphonates. See, e.g., Patani and LaVoie, Chem. Rev. 96, 3147-3176 (1996).

The phrases "parenteral administration" and "administered parenterally" are art-recognized terms, and include modes of administration other than enteral and topical administration, such as injections, and include, without limitation, intravenous, intramuscular,
intrathecal, intracapsular, intraperitoneal, transstracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

[0046] The term "treating" is art-recognized and includes inhibiting a disease, disorder or condition in a subject, e.g., impeding its progress; and relieving the disease, disorder or condition, e.g., causing regression of the disease, disorder and/or condition. Treating the disease or condition includes ameliorating at least one symptom of the particular disease or condition, even if the underlying pathophysiology is not affected.

[0047] The term "preventing" is art-recognized and includes stopping a disease, disorder or condition from occurring in a subject, which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it. Preventing a condition related to a disease includes stopping the condition from occurring after the disease has been diagnosed but before the condition has been diagnosed.

[0048] A "pharmaceutical composition" is a formulation containing the disclosed compounds in a form suitable for administration to a subject. In a preferred embodiment, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler, or a vial. The quantity of active ingredient (e.g., a formulation of the disclosed compound or salts thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved. One skilled in the art will appreciate that it is sometimes necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, intranasal, and the like. Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. In a preferred embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.
The term "flash dose" refers to compound formulations that are rapidly dispersing dosage forms.

The term "immediate release" is defined as a release of compound from a dosage form in a relatively brief period of time, generally up to about 60 minutes. The term "modified release" is defined to include delayed release, extended release, and pulsed release. The term "pulsed release" is defined as a series of releases of drug from a dosage form. The term "sustained release" or "extended release" is defined as continuous release of a compound from a dosage form over a prolonged period.

The phrase "pharmaceutically acceptable" is art-recognized. In certain embodiments, the term includes compositions, polymers and other materials and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The phrase "pharmaceutically acceptable carrier" is art-recognized, and includes, for example, pharmaceutically acceptable materials, compositions or vehicles, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of a subject composition and not injurious to the patient. In certain embodiments, a pharmaceutically acceptable carrier is non-pyrogeneric. Some examples of materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution;
(19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

[0053] The compounds of the invention are capable of further forming salts. All of these forms are also contemplated within the scope of the claimed invention.

[0054] "Pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.

[0055] For example, the salt can be an acid addition salt. One embodiment of an acid addition salt is a hydrochloride salt.

[0056] The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990). For example, salts can include, but are not limited to, the hydrochloride and acetate salts of the aliphatic amine-containing, hydroxyl amine-containing, and imine-containing compounds of the present invention.

[0057] It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same salt.

[0058] The compounds of the present invention can also be prepared as esters, for example pharmaceutically acceptable esters. For example, a carboxylic acid function group in a compound can be converted to its corresponding ester, e.g., a methyl, ethyl, or other ester. Also, an alcohol group in a compound can be converted to its corresponding ester, e.g., an acetate, propionate, or other ester.

[0059] The compounds of the present invention can also be prepared as prodrugs, for example pharmaceutically acceptable prodrugs. The terms "pro-drug" and "prodrug" are used
interchangeably herein and refer to any compound, which releases an active parent drug \textit{in vivo}. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (\textit{e.g.}, solubility, bioavailability, manufacturing, etc.) the compounds of the present invention can be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same. "Prodrugs" are intended to include any covalently bonded carriers that release an active parent drug of the present invention \textit{in vivo} when such prodrug is administered to a subject. Prodrugs the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or \textit{in vivo}, to the parent compound. Prodrugs include compounds of the present invention wherein a hydroxy, amino, sulfhydryl, carboxy, or carbonyl group is bonded to any group that may be cleaved \textit{in vivo} to form a free hydroxyl, free amino, free sulfhydryl, free carboxy or free carbonyl group, respectively.

\textbf{[0060]} Examples of prodrugs include, but are not limited to, esters (\textit{e.g.}, acetate, dialkylaminoacetates, formates, phosphates, sulfates, and benzoate derivatives) and carbamates (\textit{e.g.}, N,N-dimethylaminocarbonyl) of hydroxy functional groups, ester groups (\textit{e.g.}, ethyl esters, morpholinoethanol esters) of carboxyl functional groups, N-acyl derivatives (\textit{e.g.}, N-acetyl) N-Mannich bases, Schiff bases and enaminoes of amino functional groups, oximes, acetics, ketals and enol esters of ketone and aldehyde functional groups in compounds of Formula I, and the like, See Bundegaard, H. "Design of Prodrugs" p1-92, Elsevier, New York-Oxford (1985).

\textbf{[0061]} "Protecting group" refers to a grouping of atoms that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in Green and Wuts, Protective Groups in Organic Chemistry, (Wiley, 2.sup.nd ed. 1991); Harrison and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8 (John Wiley and Sons, 1971-1996); and Kocienski, Protecting Groups, (Verlag, 3.sup.rd ed. 2003).

\textbf{[0062]} The term "amine protecting group" is intended to mean a functional group that converts an amine, amide, or other nitrogen-containing moiety into a different chemical group that is substantially inert to the conditions of a particular chemical reaction. Amine protecting groups are preferably removed easily and selectively in good yield under conditions that do not
affect other functional groups of the molecule. Examples of amine protecting groups include, but are not limited to, formyl, acetyl, benzyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, t-butyloxycarbonyl (Boc), p-methoxybenzyl, methoxymethyl, tosyl, trifluoroacetyl, trimethylsilyl (TMS), fluorenlymethyloxycarbonyl, 2-trimethylsilyl-ethoxycarbonyl, 1-methyl-1-(4-biphenylyl) ethoxycarbonyl, allyloxycarbonyl, benzoxycarbonyl (CBZ), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, 9-fluorenlymethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), and the like. Other suitable amine protecting groups are straightforwardly identified by those of skill in the art.

Representative hydroxy protecting groups include those where the hydroxy group is either acylated or alkylated such as benzyl, and trityl ethers as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers.

The term "pharmaceutically acceptable salts" is art-recognized, and includes relatively non-toxic, inorganic and organic acid addition salts of compositions, including without limitation, therapeutic agents, excipients, other materials and the like. Examples of pharmaceutically acceptable salts include those derived from mineral acids, such as hydrochloric acid and sulfuric acid, and those derived from organic acids, such as ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like. Examples of suitable inorganic bases for the formation of salts include the hydroxides, carbonates, and bicarbonates of ammonia, sodium, lithium, potassium, calcium, magnesium, aluminum, zinc and the like. Salts may also be formed with suitable organic bases, including those that are non-toxic and strong enough to form such salts. For purposes of illustration, the class of such organic bases may include mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and triethylamine; mono-, di- or trihydroxyalkylamines such as mono-, di-, and triethanolamine; amino acids, such as arginine and lysine; guanidine; N-methylglucosamine; N-methylglucamine; L-glutamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; (trihydroxymethyl)aminoethane; and the like. See, for example, J. Pharm. Sci. 66:1-19 T1977.

A "patient," "subject," or "host" to be treated by the subject method may mean either a human or non-human animal, such as primates, mammals, and vertebrates.
The term "prophylactic or therapeutic" treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).

The terms "therapeutic agent", "drug", "medicament" and "bioactive substance" are art-recognized and include molecules and other agents that are biologically, physiologically, or pharmacologically active substances that act locally or systemically in a patient or subject to treat a disease or condition, such as retinal degeneration or other forms of retinal disease whose etiology involves aberrant clearance of all trans-retinal. The terms include without limitation pharmaceutically acceptable salts thereof and prodrugs. Such agents may be acidic, basic, or salts; they may be neutral molecules, polar molecules, or molecular complexes capable of hydrogen bonding; they may be prodrugs in the form of ethers, esters, amides and the like that are biologically activated when administered into a patient or subject.

The phrase "therapeutically effective amount" is an art-recognized term. In certain embodiments, the term refers to an amount of a therapeutic agent that, when incorporated into a polymer, produces some desired effect at a reasonable benefit/risk ratio applicable to any medical treatment. In certain embodiments, the term refers to that amount necessary or sufficient to eliminate, reduce or maintain a target of a particular therapeutic regimen. The effective amount may vary depending on such factors as the disease or condition being treated, the particular targeted constructs being administered, the size of the subject or the severity of the disease or condition. One of ordinary skill in the art may empirically determine the effective amount of a particular compound without necessitating undue experimentation. In certain embodiments, a therapeutically effective amount of a therapeutic agent for in vivo use will likely depend on a number of factors, including: the rate of release of an agent from a polymer matrix, which will depend in part on the chemical and physical characteristics of the polymer; the
identity of the agent; the mode and method of administration; and any other materials incorporated in the polymer matrix in addition to the agent.

The term "ED50" is art-recognized. In certain embodiments, ED50 means the dose of a drug, which produces 50% of its maximum response or effect, or alternatively, the dose, which produces a pre-determined response in 50% of test subjects or preparations. The term "LD50" is art-recognized. In certain embodiments, LD50 means the dose of a drug, which is lethal in 50% of test subjects. The term "therapeutic index" is an art-recognized term, which refers to the therapeutic index of a drug, defined as LD50/ED50.

The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When the substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced. Ring double bonds, as used herein, are double bonds that are formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N).

With respect to any chemical compounds, the present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include C-13 and C-14.

The chemical compounds described herein can have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom can be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and can be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic, and geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All
processes used to prepare compounds of the present invention and intermediates made therein are, where appropriate, considered to be part of the present invention. All tautomers of shown or described compounds are also, where appropriate, considered to be part of the present invention.

[0073] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent can be bonded to any atom in the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent can be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible, but only if such combinations result in stable compounds.

[0074] When an atom or a chemical moiety is followed by a subscripted numeric range (e.g., C_{1-6}), the invention is meant to encompass each number within the range as well as all intermediate ranges. For example, "C_{1-6} alkyl" is meant to include alkyl groups with 1, 2, 3, 4, 5, 6, 1-6, 1-5, 1-4, 1-3, 1-2, 2-6, 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5, and 5-6 carbons.

[0075] As used herein, "alkyl" is intended to include both branched (e.g., isopropyl, tert-butyl, isobutyl), straight-chain (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl), and cycloalkyl (e.g., alicyclic) groups (e.g., cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. Such aliphatic hydrocarbon groups have a specified number of carbon atoms. For example, C_{1-6} alkyl is intended to include C_1, C_2, C_3, C_4, C_5, and C_6 alkyl groups. As used herein, "lower alkyl" refers to alkyl groups having from 1 to 6 carbon atoms in the backbone of the carbon chain. "Alkyl" further includes alkyl groups that have oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more hydrocarbon backbone carbon atoms. In certain embodiments, a straight chain or branched chain alkyl has six or fewer carbon atoms in its backbone (e.g., C_1-C_6 for straight chain, C_3-C_6 for branched chain), for example four or fewer. Likewise, certain cycloalkyls have from three to eight carbon atoms in their ring structure, such as five or six carbons in the ring structure.

[0076] The term "substituted alkyls" refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy,
alkoxy carbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylaryl amino), acylamino (including alkylcarboxylamino, arylcarboxylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyls can be further substituted, e.g., with the substituents described above. An "alkylaryl" or an "aralkyl" moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)).

0077 As used herein, "alkenyl" is intended to include hydrocarbon chains of either straight or branched configuration having one or more carbon-carbon double bonds occurring at any stable point along the chain. For example, C₂₆ alkenyl is intended to include C₂, C₃, C₄, C₅, and C₆ alkenyl groups. Examples of alkenyl include, but are not limited to, ethenyl and propenyl.

0078 As used herein, "alkynyl" is intended to include hydrocarbon chains of either straight or branched configuration having one or more carbon-carbon triple bonds occurring at any stable point along the chain. For example, C₂₆ alkynyl is intended to include C₂, C₃, C₄, C₅, and C₆ alkynyl groups. Examples of alkynyl include, but are not limited to, ethynyl and propynyl.

0079 Furthermore, "alkyl", "alkenyl", and "alkynyl" are intended to include moieties which are diradicals, i.e., having two points of attachment. A nonlimiting example of such an alkyl moiety that is a diradical is --CH₂CH₂--, i.e., a C₂ alkyl group that is covalently bonded via each terminal carbon atom to the remainder of the molecule.

0080 "Aryl" includes groups with aromaticity, including 5- and 6-membered "unconjugated", or single-ring, aromatic groups that may include from zero to four heteroatoms, as well as "conjugated", or multicyclic, systems with at least one aromatic ring. Examples of aryl groups include benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, and pyrimidine,
and the like. Furthermore, the term "aryl" includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoazole, benzodioxazole, benzothiazole, benzimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthidine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles", "heterocycles," "heteroaryls" or "heteroaaromatics". The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarboxyloxy, arylcarboxyloxy, alkoxy carbonyloxy, arloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, ary lacarbonyl, aralkylcarbonyl, alkylcarbonyl, alkoxy carbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diaryl amino, and alkyaryl amino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfanyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings, which are not aromatic so as to form a multicyclic system (e.g., tetralin, methylenedioxyphenyl).

[0081] The terms "heterocycl" or "heterocyclic group" include closed ring structures, e.g., 3- to 10-, or 4- to 7-membered rings, which include one or more heteroatoms. "Heteroatom" includes atoms of any element other than carbon or hydrogen. Examples of heteroatoms include nitrogen, oxygen, sulfur and phosphorus.

[0082] Heterocyclic groups can be saturated or unsaturated and include pyrrolidine, oxolane, thiolane, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, and sultones. Heterocyclic groups such as pyrrole and furan can have aromatic character. They include fused ring structures such as quinoline and isoquinoline. Other examples of heterocyclic groups include pyridine and purine. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, hydroxyl, alkylcarboxyloxy, arylcarboxyloxy, alkoxy carbonyloxy, arloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxy carbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxy,
phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety. Heterocyclic groups can also be substituted at one or more constituent atoms with, for example, a lower alkyl, a lower alkenyl, a lower alkoxy, a lower alkylthio, a lower alkyaminio, a lower alkyloxycarbonyl, a nitro, a hydroxyl, -CF₃, or --CN, or the like.

[0083] As used herein, "halo" or "halogen" refers to fluoro, chloro, bromo, and iodo.
"Counterion" is used to represent a small, negatively charged species such as fluoride, chloride, bromide, iodide, hydroxide, acetate, and sulfate.

[0084] "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation, and as appropriate, purification from a reaction mixture, and formulation into an efficacious therapeutic agent.

[0085] "Free compound" is used herein to describe a compound in the unbound state.

[0086] "Extinction coefficient" is a constant used in the Beer-Lambert Law which relates the concentration of the substance being measured (in moles) to the absorbance of the substance in solution (how well the substance in solution blocks light beamed through it from getting out on the other side). It is an indicator of how much light a compound absorbs at a particular wavelength.

[0087] In the specification, the singular forms also include the plural, unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In the case of conflict, the present specification will control.

[0088] Throughout the description, where compositions are described as having, including, or comprising, specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components. Similarly, where methods or processes are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps. Further, it should be understood that the order of steps
or order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions can be conducted simultaneously.

[0089] "Small molecule" is an art-recognized term. In certain embodiments, this term refers to a molecule, which has a molecular weight of less than about 2000 amu, or less than about 1000 amu, and even less than about 500 amu.

[0090] All percentages and ratios used herein, unless otherwise indicated, are by weight.

[0091] The "retina" is a region of the central nervous system with approximately 150 million neurons. It is located at the back of the eye where it rests upon a specialized epithelial tissue called retinal pigment epithelium or RPE. The retina initiates the first stage of visual processing by transducing visual stimuli in specialized neurons called "photoreceptors". Their synaptic outputs are processed by elaborate neural networks in the retina and then transmitted to the brain. The retina has evolved two specialized classes of photoreceptors to operate under a wide range of light conditions. "Rod" photoreceptors transduce visual images under low light conditions and mediate achromatic vision. "Cone" photoreceptors transduce visual images in dim to bright light conditions and mediate both color vision and high acuity vision.

[0092] Every photoreceptor is compartmentalized into two regions called the "outer" and "inner" segment. The inner segment is the neuronal cell body containing the cell nucleus. The inner segment survives for a lifetime in the absence of retinal disease. The outer segment is the region where the light sensitive visual pigment molecules are concentrated in a dense array of stacked membrane structures. Part of the outer segment is routinely shed and regrown in a diurnal process called outer segment renewal. Shed outer segments are ingested and metabolized by RPE cells.

[0093] The "macula" is the central region of the retina, which contains the fovea where visual images are processed by long slender cones in high spatial detail ("visual acuity"). "Macular degeneration" is a form of retinal neurodegeneration, which attacks the macula and destroys high acuity vision in the center of the visual field. AMD begins in a "dry form" characterized by residual lysosomal granules called lipofuscin in RPE cells, and by extracellular deposits called "drusen". Drusen contain cellular waste products excreted by RPE cells.
"Lipofuscin" and drusen can be detected clinically by ophthalmologists and quantified using fluorescence techniques. They can be the first clinical signs of macular degeneration.

Lipofuscin contains aggregations of A2E. Lipofuscin accumulates in RPE cells and poisons them by multiple known mechanisms. As RPE cells become poisoned, their biochemical activities decline and photoreceptors begin to degenerate. Extracellular drusen may further compromise RPE cells by interfering with their supply of vascular nutrients. Drusen also trigger inflammatory processes, which leads to choroidal neovascular invasions of the macula in one patient in ten who progresses to wet form AMD. Both the dry form and wet form progress to blindness.

"ERG" is an acronym for electroretinogram, which is the measurement of the electric field potential emitted by retinal neurons during their response to an experimentally defined light stimulus. ERG is a non-invasive measurement, which can be performed on either living subjects (human or animal) or a hemisected eye in solution that has been removed surgically from a living animal.

As used herein, the term "RAL" means retinaldehyde. "Free RAL" is defined as RAL that is not bound to a visual cycle protein. The terms "trans-RAL" and "all-trans-RAL" are used interchangeably and mean all-trans-retinaldehyde.

The present invention relates to compounds and methods of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina. The ocular disorder can include, for example, retinal disorders, such as macular degeneration, including age-related macular degeneration, Stargardt disease, and retinitis pigmentosa.

Figs. 1 and 2 show the retinoid flow in the visual cycle including condensation of all-trans-RAL, and all-trans-RAL clearance. After 11-cis-retinal binds to opsin from rhodopsin, the resulting visual chromophore 11-cis-retinylidene is photoisomerized to all-trans-retinylidene, the precursor or all-trans-RAL that is later released. Most of the all-trans-RAL dissociates from opsin into the cytoplasm before it is reduced to all-trans-retinol by RDHs including RDH8. The fraction of all-trans-RAL that dissociates into disc lumens is transported by ABCA4 before it is reduced. Thus, condensation products can be generated both within the disc lumens and the cytoplasm before it is reduced.
It was found that all-trans-RAL that has escaped sequestering by opsins in photoreceptor outer segments of the retina is toxic to retina cells and that aberrant all-trans-RAL clearance from the inner disc membrane to the outer disc membrane can cause retinal degeneration. The mechanism of all-trans-RAL toxicity can include plasma membrane permeability and mitochondrial poisoning that leads to caspase activation and mitochondrial associated cell death.

In accordance with the present invention, compounds used to treat an ocular disorder associated with aberrant all-trans-RAL clearance can include primary amines (i.e., primary amine compounds) that form reversible Schiff-bases with free all-trans-RAL, which has escaped sequestering in photoreceptor outer segments of the retina without adversely affecting normal retinoid cycle. Formation of a reversible Schiff base between RAL and the primary amine compounds of the present invention can control or modulate all-trans-RAL levels in the retina and prevent retina degeneration. The stability of the Schiff-bases formed between the primary amine compounds of the present invention and the free RAL under physiologic conditions of the retina can be used to determine the efficacy of these compounds in treating the ocular disorder. The stability of the Schiff-bases formed from the primary amine compounds should be such that the level of free RAL in the retina is reduced to a level that is effective to mitigate retinal degeneration but not impair the normal retinoid cycle.

In an aspect of the invention, the primary amine compounds of the present invention that can form stable Schiff-bases with all-trans-RAL under physiological conditions of the retina and that can inhibit retinal degeneration upon administration to a subject can be selected using an in vitro assay that measures the ability of a primary amine compound to form Schiff base with retinal under physiological condition of the retina and in vivo assays that measure respectively 11-cis-retinal formation and the optical coherence tomography score of retinas of Rdh8<sup>−/−</sup>Abca4<sup>−/−</sup> mice. Primary amine compounds that form a Schiff-base with all-trans-RAL or its metabolite under physiologic conditions of the retina and that when administered to a Rdh8<sup>−/−</sup>Abca4<sup>−/−</sup> mouse increase the optical coherence tomography score of the mouse to at least about 2.5 and increase 11-cis-retinal amount at least about 30% in comparison to untreated control animal are effective in treating retinal degeneration in a subject associated
with aberrant all-trans-RAL clearance. Primary amine compounds that do not form a form a Schiff-base with all-trans-RAL or its metabolite under physiologic conditions of the retina or which when administered to a Rdh8+/Abca4+/ mouse do not increase the optical coherence tomography score of the mouse to at least about 2.5 and increase 11-cis-retinal amount at least about 30% in comparison to untreated control animal, were found to be ineffective in treating retinal degeneration in a subject associated with aberrant all-trans-RAL clearance.

[00102] In an aspect of the present invention, the primary amine compound of the present can include the structural formula (I):

\[
\text{R}_1-\text{NH}_2
\]

(I)

wherein R_1 is an aliphatic and/or aromatic compound.

[00103] Primary amine compounds having formula I that are used to treat retinal degeneration in accordance with the present invention can upon administration to the subject form a reversible Schiff-base with the all-trans-RAL without adversely affecting normal retinoid cycle performance and when administered to a Rdh8+/Abca4+/ mouse increase the optical coherence tomography score of the mouse to at least about 2.5 and increase 11-cis-retinal amount at least about 30% in comparison to untreated control animal. Primary amine compounds in accordance with the present invention however are not a local anesthetic, which includes an aromatic amine that demonstrates sodium channel blockade when administered to the subject.

[00104] Advantageously, the primary amine compounds in accordance with the present invention do not inhibit RPE65 enzymatic activity or any other proteins involved in retinoid metabolism in the eye of the subject. The primary amine compounds can reduce the formation of A2E and/or retinal dimer in the subject’s retina, promote 11-cis-retinal production in the subject, and does not cause night blindness.

[00105] In an aspect of the invention, primary compounds having formula I that upon administration to a subject form a reversible Schiff-base with the all-trans-RAL without adversely affecting normal retinoid cycle performance and that when administered to a Rdh8+/ Abca4+/ mouse increase the optical coherence tomography score of the mouse to at least about
2.5 and increase 11-cis-retinal amount at least about 30% in comparison to untreated control animal can be selected using the methods described in the Examples from known primary amine compounds. In an aspect of the invention, the primary amine compounds can include known primary amine compounds having the following structural formulas:
wherein $R_2$ is hydrogen or (C$_1$-C$_6$) straight chain or branched unsubstituted or substituted alkyl;

$R_3$ is straight or branched unsubstituted or substituted alkyl of from 1 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylecycloalkyl, -alkylalkoxy, -alkyl, OH, -alkylphenyl, -alkylphenoxy, -phenyl or substituted phenyl;

$R_4$ is hydrogen or (C$_1$-C$_6$) straight chain or branched unsubstituted or substituted alkyl, or carboxyl;

Ar is phenyl which is unsubstituted or substituted with 1-5 of $R_7$, wherein $R_7$ is independently selected from the group consisting of:

1. halogen,
2. C$_{1-6}$ alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens,
3. OCS$_{1-6}$ alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens, and
4. CN;

$X_1$ is selected from the group consisting of:
(1) N, and
(2) CR₆;
R₅ and R₆ are independently selected from the group consisting of:
(1) hydrogen,
(2) CN,
(3) C₁₋₁₀ alkyl, which is linear or branched and which is unsubstituted or
substituted with 1-5 halogens or phenyl, which is unsubstituted or substituted with 1-5
substituents independently selected from halogen, CN, OH, R₈, OR₈, NHSO₂ R₈, SO₂ R₈, CO₂ H, and
CO₂ C₁₋₆ alkyl, wherein the CO₂ C₁₋₆ alkyl is linear or branched,
(4) phenyl which is unsubstituted or substituted with 1-5 substituents
independently selected from halogen, CN, OH, R₈, OR₈, NHSO₂ R₈, SO₂ R₈, CO₂ H, and CO₂
C₁₋₆ alkyl, wherein the CO₂ C₁₋₆ alkyl is linear or branched, and
(5) a 5- or 6-membered heterocycle which may be saturated or unsaturated
comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being
unsubstituted or substituted with 1-3 substituents independently selected from oxo, OH, halogen,
C₁₋₆ alkyl, and OC₁₋₆ alkyl, wherein the C₁₋₆ alkyl and OC₁₋₆ alkyl are linear or branched and
optionally substituted with 1-5 halogens;
R₉ is C₁₋₆ alkyl, which is linear or branched and which is unsubstituted or
substituted with 1-5 groups independently selected from halogen, CO₂ H, and CO₂ C₁₋₆ alkyl,
wherein the CO₂ C₁₋₆ alkyl is linear or branched;
R₉ and R₁₀ may be the same or different and are hydrogen, straight or branched
alkyl of from one to six carbon atoms, lower alkylaryl, lower alkenyl, phenyl, CF₃, hydroxy,
lower alkoxy, lower alkylthio, lower alkylsulphonyl, CF₃ O, at the six position halogen, nitro,
carboxy, lower alkoxy carbonyl, NR₁₁R₁₂CO, NR₁₁R₁₂, R₁₁CONR₁₂, CN, NR₁₁R₁₂SO₂, wherein
R₁₁ and R₁₂ may be the same or different and are hydrogen, lower alkyl, or aryl; R₉ and R₁₀ may
together form a carbocyclic or methylenedioxy ring;
R₁₄ is cyano, cyanomethyl, methoxymethyl, or ethoxymethyl;
X₂ is O, N(H), or S, het is a 5 or 6-membered heterocycle, n is 0, 1, 2, or 3, and
each D is an unbranched lower alkyl group;
U is a substituent selected from halogen atom; cyano; lower alkyl wherein one or more hydrogen atoms on the lower alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms; lower alkythio wherein one or more hydrogen atoms on the alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl; lower alkylsulfonyl wherein one or more hydrogen atoms on the alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl; hydroxy; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxy carbonyl; carbamoyl; N-lower alkylcarbonyl; N,N-di-lower alkyaminocarbonyl; amino; N-lower alkylamino; N,N-di-lower alkylamino; formylamino; lower alkylcarbonylamino; aminosulfonylamino; (N-lower alkylamino)sulfonylamino; (N,N-di-lower alkylamino)sulfonylamino; aryl, optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, aryl and amino; and a monocyclic or bicyclic heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms;

W, X, Y, and Z are each, independently, N, S, O, CU or CH, such that at least one of W, X, Y, and Z is N;

A is

\[
\begin{align*}
\text{D is unbranched lower alkyl;} \\
\text{R}_{15} \text{ and } R_{16} \text{ are each independently substituted or unsubstituted } C_1, C_2, C_3, C_4, C_5, C_6, C_7, \text{ or } C_8, \text{ straight chain alkyl, or substituted or unsubstituted } C_3, C_4, C_5, C_6, C_7, \text{ or } C_8, \text{ branched chain alkyl;} \\
\text{L is a single bond or CH}_2; \\
m \text{ is } 0, 1, \text{ or } 2; \\
n \text{ is } 0, 1, 2, 3, \text{ or } 4; \\
Y_1 \text{ is } -(\text{CH}_2)_2 - , -(\text{CH}_3)_2 - , -\text{CH}_2 \text{ CH(} \text{CH}_3)_2 - \text{ or } -\text{CH}_2 \text{ C(} \text{CH}_3)_2 - ;
\end{align*}
\]
$R_{17}$ is aryl or heteroaryl;
$R_{18}$ and $R_{19}$ are each independently $C_1$-$C_4$ alkyl or 2-methoxyethyl;
$R_{20}$ is hydrogen, $C_1$-$C_4$ alkyl, 2-$(C_1$-$C_4$ alkoxy)ethyl, cyclopropylmethyl, benzyl, or $-$(CH$_2$)$_m$COR$_{21}$ where $m$ is 1, 2 or 3 and $R_{21}$ is hydroxy, $C_1$-$C_4$ alkoxy or $-NR_{22}$ where $R_{22}$ hydrogen or $C_1$-$C_4$ alkyl;
$R_{23}$ and $R_{24}$ can be the same or different and are hydrogen, methyl, or ethyl as well as pharmaceutically acceptable salts thereof.

[00106] In a further aspect of the invention, the primary amine compound can be selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
[00107] In a still further aspect of the invention, the primary amine compound can be selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

[00108] In another aspect of the invention, the primary compound can have the following structural formula:

wherein Ar is phenyl which is unsubstituted or substituted with 1-5 substituents which are independently selected from the group consisting of: (1) fluoro, (2) bromo, and (3) CF₃, R₂ is selected from the group consisting of: (1) hydrogen, and (2) C₁₋₆ alkyl, which is linear or branched and which is unsubstituted or substituted with phenyl or 1-5 fluoro.

[00109] In yet another aspect of the present invention it is more preferred that Ar is selected from the group consisting of: (1) phenyl, (2) 2-fluorophenyl, (3) 3,4-difluorophenyl, (4) 2,5-difluorophenyl, (5) 2,4,5-trifluorophenyl, (6) 2-fluoro-4-(trifluoromethyl)phenyl, and (7) 4-bromo-2,5-difluorophenyl and R5 is selected from the group consisting of: (1) hydrogen, (2) methyl, (3) ethyl, (4) CF₃, (5) CH₂CF₃, (5) CF₂CF₃ (6) phenyl, and (7) benzyl.
[00110] In another aspect of the invention the primary amine compound can be a monobasic dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine of the following structural formula:

![Structural formula of the dihydrogenphosphate salt](image)

or a crystalline hydrate thereof. In particular, the instant invention provides a crystalline monohydrate of the dihydrogenphosphate salt.

[00111] The dihydrogenphosphate salt shown above has a center of asymmetry at the stereogenic carbon atom indicated with an * and can thus occur as a racemate, racemic mixture, and single enantiomers, with all isomeric forms being included in the present invention. The separate enantiomers, substantially free of the other, are included within the scope of the invention, as well as mixtures of the two enantiomers. Monobasic dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine

[00112] In a further aspect of the present invention, the primary amine compound can be a dihydrogenphosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-triflorophenyl) butan-2-amine of the following structural formula:

![Structural formula of the dihydrogenphosphate salt](image)

or a crystalline hydrate thereof.
In yet another aspect of the present invention, the primary amine compound can be a dihydrogenphosphate salt of (2S)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazi- n-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine of the following structural formula:

![Chemical Structure](attachment:image.png)

or a crystalline hydrate thereof.

In still another aspect of the invention, the primary amine compound is a compound having the following structural formula:

![Chemical Structure](attachment:image.png)

or a pharmaceutically acceptable salt thereof

wherein R₂ is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl;

R₃ is straight or branched alkyl of from 1 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH -alkylphenyl, -alkylphenoxy, -phenyl or substituted phenyl;

R₄ is hydrogen, and R₂ is straight or branched alkyl of from 1 to 6 carbon atoms or phenyl when R₃ is methyl.

In yet another aspect of the invention, the primary amine compound can have the following structural formula:
or a pharmaceutically acceptable salt thereof;
wherein R₂ is methyl, R₃ is an alkyl, and R₄ is a hydrogen.

[00116] Specific examples of compounds of above noted formulas are selected from:
3-Aminomethyl-5-methylheptanoic acid; 3-Aminomethyl-5-methyl-octanoic acid;
3-Aminomethyl-5-methyl-nonanoic acid; 3-Aminomethyl-5-methyl-decanoic acid;
3-Aminomethyl-5-methyl-undecanoic acid; 3-Aminomethyl-5-methyl-dodecanoic acid;
3-Aminomethyl-5-methyl-tridecanoic acid; 3-Aminomethyl-5-cyclopropyl-hexanoic acid;
3-Aminomethyl-5-cyclobutyl-hexanoic acid; 3-Aminomethyl-5-cyclopentyl-hexanoic acid;
3-Aminomethyl-5-cyclohexyl-hexanoic acid; 3-Aminomethyl-5-trifluoromethyl-hexanoic acid;
3-Aminomethyl-5-phenyl-hexanoic acid; 3-Aminomethyl-5-(2-chlorophenyl)-hexanoic acid;
3-Aminomethyl-5-(3-chlorophenyl)-hexanoic acid; 3-Aminomethyl-5-(4-chlorophenyl)-hexanoic acid;
3-Aminomethyl-5-(2-methoxyphenyl)-hexanoic acid; 3-Aminomethyl-5-(3-methoxyphenyl)-hexanoic acid;
3-Aminomethyl-5-(4-methoxyphenyl)-hexanoic acid; and
3-Aminomethyl-5-(phenylmethyl)-hexanoic acid; (3R,4S)-3-Aminomethyl-4,5-dimethyl-hexanoic acid;
3-Aminomethyl-4,5-dimethyl-hexanoic acid; (3R,4S)-3-Aminomethyl-4,5-dimethyl-hexanoic acid MP; (3S,4S)-3-Aminomethyl-4,5-dimethyl-hexanoic acid;
(3R,4R)-3-Aminomethyl-4,5-dimethyl-hexanoic acid MP; 3-Aminomethyl-4-isopropyl-hexanoic acid;
3-Aminomethyl-4-isopropyl-heptanoic acid; 3-Aminomethyl-4-isopropyl-octanoic acid;
3-Aminomethyl-4-isopropyl-nonanoic acid; 3-Aminomethyl-4-isopropyl-decanoic acid;
3-Aminomethyl-4-phenyl-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-5-methoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-ethoxy-hexanoic acid; (3S,5S)-3-Aminomethyl-5-propoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-isopropoxy-hexanoic acid; (3S,5S)-3-Aminomethyl-5-tert-butoxy-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-fluoromethoxy-hexanoic acid; (3S,5S)-3-Aminomethyl-5-(2-fluoro-ethoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-(3,3,3-trifluoro-
propoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-phenoxy-hexanoic acid; (3S,5S)-3-
Aminomethyl-5-(4-chloro-phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-(3-chloro-
phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-(2-chloro-phenoxy)-hexanoic acid; (3S,5S)-
3-Aminomethyl-5-(4-fluoro-phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-(3-fluoro-
phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-(2-fluoro-phenoxy)-hexanoic acid; (3S,5S)-
3-Aminomethyl-5-(4-methoxy-phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-(3-methoxy-
phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-(2-methoxy-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-(4-nitro-phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-(3-nitro-
phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-(2-nitro-phenoxy)-hexanoic acid; (3S,5S)-3-
Aminomethyl-6-hydroxy-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-methoxy-5-
methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-ethoxy-5-methyl-hexanoic acid; (3S,5S)-3-
Aminomethyl-6-propoxy-hexanoic acid; (3S,5S)-3-Aminomethyl-6-isopropoxy-5-
methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-tert-butoxy-5-methyl-hexanoic acid; (3S,5S)-
3-Aminomethyl-6-fluoromethoxy-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(2-fluoro-
ethoxy)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-6-(3,3,3-trifluoro-propoxy)-
hexanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-6-phenoxy-hexanoic acid; (3S,5S)-3-
Aminomethyl-6-(4-chloro-phenoxy)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(3-
chloro-phenoxy)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(2-chloro-phenoxy)-5-
methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(4-fluoro-phenoxy)-5-methyl-hexanoic acid;
(3S,5S)-3-Aminomethyl-6-(3-fluoro-phenoxy)-5-methyl-hexanoic acid; (3S,5S)-3-
Aminomethyl-6-(2-fluoro-phenoxy)-5-methyl-hexanoic acid; (3S,5S)-3-
Aminomethyl-6-(4-methoxy-phenoxy)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(3-
methoxy-phenoxy)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(2-methoxy-phenoxy)-5-
methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-6-(4-trifluoromethyl-phenoxy)-hexanoic acid; (3S,5S)-3-
Aminomethyl-5-methyl-6-(3-trifluoromethyl-phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-
5-methyl-6-(2-trifluoromethyl-phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-
methyl-6-(4-nitro-phenoxy)-hexanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-6-(3-nitro-phenoxy)-hexanoic acid;
(3S,5S)-3-Aminomethyl-5-methyl-6-(2-nitro-phenoxy)-hexanoic acid; (3S,5S)-3-
Aminomethyl-6-benzyl oxy-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-7-hydroxy-5-
methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-methoxy-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-ethoxy-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-propoxy-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-isopropoxy-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-tert-butoxy-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-fluoromethoxy-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-(2-fluoro-ethoxy)-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-7-(3,3,3-trifluoropropoxy)-heptanoic acid; (3S,5S)-3-Aminomethyl-7-benzylxoy-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-7-phenoxy-heptanoic acid; (3S,5S)-3-Aminomethyl-7-(4-chloro-phenoxy)-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-(3-chloro-phenoxy)-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-(2-chloro-phenoxy)-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-(4-fluorophenoxy)-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-(3-fluorophenoxy)-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-(2-fluorophenoxy)-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-(4-methoxy-phenoxy)-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-(3-methoxy-phenoxy)-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-7-(2-methoxy-phenoxy)-5-methyl-heptanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-7-(4-trifluoromethyl-phenoxy)-heptanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-7-(3-trifluoromethyl-phenoxy)-heptanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-7-(2-trifluoromethyl-phenoxy)-heptanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-7-(4-nitrophenoxy)-heptanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-7-(3-nitrophenoxy)-heptanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-7-(2-nitrophenoxy)-heptanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-6-phenyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(4-chloro-phenyl)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(3-chloro-phenyl)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(2-chloro-phenyl)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(4-methoxy-phenyl)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(3-methoxy-phenyl)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(2-methoxy-phenyl)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(4-fluoro-phenyl)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(3-fluoro-phenyl)-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-6-(2-fluoro-phenyl)-5-methyl-hexanoic acid; (3S,5R)-3-Aminomethyl-5-methyl-7-phenyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-(4-chloro-phenyl)-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-(3-
chloro-phenyl)-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-(2-chloro-phenyl)-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-(4-methoxy-phenyl)-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-(3-methoxy-phenyl)-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-(2-methoxy-phenyl)-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-(4-fluoro-phenyl)-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-(3-fluoro-phenyl)-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-(2-fluoro-phenyl)-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-5-methyl-oct-7-enoic acid; (3S,5R)-3-Aminomethyl-5-methyl-non-8-enoic acid; (E)-(3S,5S)-3-Aminomethyl-5-methyl-oct-6-enoic acid; (Z)-(3S,5S)-3-Aminomethyl-5-methyl-oct-6-enoic acid; (Z)-(3S,5S)-3-Aminomethyl-5-methyl-non-6-enoic acid; (E)-(3S,5S)-3-Aminomethyl-5-methyl-non-6-enoic acid; (E)-(3S,5R)-3-Aminomethyl-5-methyl-non-7-enoic acid; (Z)-(3S,5R)-3-Aminomethyl-5-methyl-non-7-enoic acid; (Z)-(3S,5R)-3-Aminomethyl-5-methyl-dec-7-enoic acid; (E)-(3S,5R)-3-Aminomethyl-5-methyl-undec-7-enoic acid; (3S,5S)-3-Aminomethyl-5,6,6-trimethyl-heptanoic acid; (3S,5S)-3-Aminomethyl-5,6-dimethyl-heptanoic acid; (3S,5S)-3-Aminomethyl-5-cyclopropyl-hexanoic acid; (3S,5S)-3-Aminomethyl-5-cyclobutyl-hexanoic acid; (3S,5S)-3-Aminomethyl-5-cyclopentyl-hexanoic acid; (3S,5S)-3-Aminomethyl-5-cyclohexyl-hexanoic acid; (3S,5R)-3-Aminomethyl-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid; (3S,5R)-3-Aminomethyl-5-methyl-nonanoic acid; (3S,5R)-3-Aminomethyl-5-methyl-decanoic acid; (3S,5R)-3-Aminomethyl-5-methyl-undecanoic acid; (3S,5R)-3-Aminomethyl-5-methyl-dodecanoic acid; (3S,5R)-3-Aminomethyl-5,9-dimethyl-dodecanoic acid; (3S,5R)-3-Aminomethyl-5,7-dimethyl-octanoic acid; (3S,5R)-3-Aminomethyl-5,8-dimethyl-nonanoic acid; (3S,5R)-3-Aminomethyl-6-cyclopropyl-5-methyl-hexanoic acid; (3S,5R)-3-Aminomethyl-6-cyclohexyl-5-methyl-hexanoic acid; (3S,5R)-3-Aminomethyl-6-cyclopentyl-5-methyl-hexanoic acid; (3S,5R)-3-Aminomethyl-6-cyclobutyl-5-methyl-hexanoic acid; (3S,5R)-3-Aminomethyl-6-cyclopentyl-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-cyclobutyl-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-cyclopentyl-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-7-cyclohexyl-5-methyl-heptanoic acid; (3S,5R)-3-Aminomethyl-8-cyclopropyl-5-methyl-octanoic acid; (3S,5R)-3-Aminomethyl-8-cyclobutyl-5-methyl-octanoic acid; (3S,5R)-3-Aminomethyl-8-cyclopentyl-5-methyl-octanoic acid; (3S,5R)-3-Aminomethyl-8-cyclohexyl-5-methyl-octanoic acid; (3S,5S)-3-Aminomethyl-6-
fluoro-5-methyl-hexanoic acid; (3S,5S)-3-Aminomethyl-7-fluoro-5-methyl-heptanoic acid; 
(3S,5R)-3-Aminomethyl-8-fluoro-5-methyl-octanoic acid; (3S,5R)-3-Aminomethyl-9-fluoro-5-
methyl-nonanoic acid; (3S,5S)-3-Aminomethyl-7,7,7-trifluoro-5-methyl-heptanoic acid; 
(3S,5R)-3-Aminomethyl-8,8,8-trifluoro-5-methyl-octanoic acid; (3S,5R)-3-Aminomethyl-5-
methyl-8-phenyl-octanoic acid; (3S,5S)-3-Aminomethyl-5-methyl-6-phenyl-hexanoic acid; and 
(3S,5R)-3-Aminomethyl-5-methyl-7-phenyl-heptanoic acid. Methods of synthesizing the above 
noted compounds are described in PCT Patent Application No. WO 00/76958, which is 
incorporated herein by reference in its entirety.

[00117] In another aspect of the invention, the primary amine compound can have the 
following structural formula:

\[
\begin{align*}
\text{NH}_2
\end{align*}
\]

\[
\begin{align*}
\text{F}_3\text{C} & \text{C}_\text{N} \\
\text{(CH}_2\text{)}_4\text{R}_14
\end{align*}
\]

wherein R\textsubscript{14} is a methoxymethyl or ethoxymethyl groups. Methods of 
synthesizing the above noted compounds are described in U.S. Patent No. 4,085,225, which is 
incorporated herein by reference in its entirety.

[00118] In a further aspect of the invention, the primary amine compound can have the 
following structural formula:

\[
\begin{align*}
\text{R}_{18}\text{OOC} & \text{H} \\
\text{R}_{17} & \text{COOR}_{19} \\
\text{H}_3\text{C} & \text{O} \\
\text{C} & \text{Y}_1 \text{NHR}_{20}
\end{align*}
\]
wherein $R_{17}$ is 2-chlorophenyl, 2-fluorophenyl, 2-methoxyphenyl, 3-chlorophenyl, 2-chloro-3-hydroxyphenyl, 2-chloro-6-fluorophenyl, unsubstituted phenyl or 2,3-dichlorophenyl; $R_{18}$ is preferably CH$_3$; $R_{19}$ is C$_2$H$_5$; $R_{20}$ is H or CH$_3$; and $Y_1$ is (CH$_2$)$_2$ or CH$_2$ CH(CH$_3$)$_2$.

Methods of synthesizing the above noted compounds are described in U.S. Patent No. 4,572,909, which is herein incorporated by reference in its entirety.

[00119] In a further aspect of the invention, the primary amine compound can have the following structural formula:

![Chemical Structure]

wherein $R_9$ and $R_{10}$ are hydrogen, straight or branched alkyl of from one to six carbon atoms, lower alkylaryl, alkenyl, phenyl, CF$_3$, lower alkoxy, lower alkylthio, lower alkylsulphonyl, CF$_3$ O at the six position, halogen, nitro, NR$_{11}$R$_{12}$, R$_{11}$CONR$_{11}$, or CN.

[00120] Examples of compounds having the above noted structure are:

- 2-aminobenzothiazole, 2-amino-6-methylbenzothiazole, 2-amino-4-methylbenzothiazole,
- 2-amino-6-trifluoromethylbenzothiazole, 2-amino-4-trifluoromethylbenzothiazole, 2-amino-5-trifluoromethylbenzothiazole, 2-amino-6-trifluoromethoxybenzothiazole, 2-amino-6-ethoxybenzothiazole, 2-amino-6-nitrobenzothiazole, 2-amino-4-methoxybenzothiazole, 2-amino-5-methoxybenzothiazole, 2-amino-4,6-dimethylbenzothiazole, 2-amino-6-bromobenzothiazole,
- 2-amino-6-chlorobenzothiazole, 2-amino-4-chlorobenzothiazole, 2-amino-6-fluorobenzothiazole, 2-amino-naptho[1,2-d]thiazole, 2-ethylaminobenzothiazole, 2-[(2-(1-methyl-2-pyrrolidinyl)ethyl)amino]-benzothiazole, 2-amino-6-methylsulphonylbenzothiazole, 2-amino-4,6-difluorobenzothiazole, 2-amino-6-methylthiobenzothiazole, and 2-benzylaminobenzothiazole. Methods of synthesizing the above noted compounds are described in U.S. Patent No. 4,826,860, which is herein incorporated by reference in its entirety.

[00121] The primary amine compounds used in methods of the present invention can be administered to the subject to treat the ocular disorder (e.g., macular degeneration or Stargardt disease) using standard methods including, for example, ophthalmic, topical, parenteral, subcutaneous, intravenous, intraarticular, intrathecal, intramuscular, intraperitoneal, intradermal
injections, or by transdermal, buccal, oromucosal, oral routes or via inhalation. The particular approach and dosage used for a particular subject depends on several factors including, for example, the general health, weight, and age of the subject. Based on factors such as these, a medical practitioner can select an appropriate approach to treatment.

[00122] Treatment according to the present methods of the invention can be altered, stopped, or re-initiated in a subject depending on the status of ocular disorder. Treatment can be carried out as intervals determined to be appropriate by those skilled in the art. For example, the administration can be carried out 1, 2, 3, or 4 times a day. In another aspect of the present invention, the primary amine compound can be administered after induction of macular degeneration has occurred.

[00123] The methods of the present invention include administering to the subject a therapeutically effective amount of the primary amine compound. Determination of a therapeutically effective amount is within the capability of those skilled in the art. The exact formulation, route of administration, and dosage can be chosen by the individual physician in view of the subject’s condition.


[00125] In one example, the primary amine compound can be provided in ophthalmic preparation that can be administered to the subject’s eye. The ophthalmic preparation can contain the primary amine compound in a pharmaceutically acceptable solution, suspension or ointment. Some variations in concentration will necessarily occur, depending on the particular primary amine compound employed, the condition of the subject to be treated and the like, and the person responsible for treatment will determine the most suitable concentration for the
individual subject. The ophthalmic preparation can be in the form of a sterile aqueous solution containing, if desired, additional ingredients, for example, preservatives, buffers, tonicity agents, antioxidants, stabilizers, nonionic wetting or clarifying agents, and viscosity increasing agents.

[00126] Examples of preservatives for use in such a solution include benzalkonium chloride, benzethonium chloride, chlorobutanol, thimerosal and the like. Examples of buffers include boric acid, sodium and potassium bicarbonate, sodium and potassium borates, sodium and potassium carbonate, sodium acetate, and sodium biphosphate, in amounts sufficient to maintain the pH at between about pH 6 and about pH 8, and for example, between about pH 7 and about pH 7.5. Examples of tonicity agents are dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, and sodium chloride.

[00127] Examples of antioxidants and stabilizers include sodium bisulfite, sodium metabisulfite, sodium thiosulfite, and thiourea. Examples of wetting and clarifying agents include polysorbate 80, polysorbate 20, poloxamer 282 and tyloxapol. Examples of viscosity-increasing agents include gelatin, glycerin, hydroxyethylcellulose, hydroxyethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, and carboxymethylcellulose. The ophthalmic preparation will be administered topically to the eye of the subject in need of treatment by conventional methods, for example, in the form of drops or by bathing the eye in the ophthalmic solution.

[00128] The primary amine compound can also be formulated for topical administration through the skin. "Topical delivery systems" also include transdermal patches containing the ingredient to be administered. Delivery through the skin can further be achieved by iontophoresis or electrotaneous, if desired.

[00129] Formulations for topical administration to the skin include, for example, ointments, creams, gels and pastes comprising the primary amine compound in a pharmaceutical acceptable carrier. The formulation of the primary amine compound for topical use includes the preparation of oleaginous or water-soluble ointment bases, as is well known to those in the art. For example, these formulations may include vegetable oils, animal fats, and, for example, semisolid hydrocarbons obtained from petroleum. Particular components used may include white
ointment, yellow ointment, cetyl esters wax, oleic acid, olive oil, paraffin, petrolatum, white petrolatum, spermacet, starch glycerite, white wax, yellow wax, lanolin, anhydrous lanolin and glycercy monostearate. Various water-soluble ointment bases may also be used, including glycol ethers and derivatives, polyethylene glycols, polyoxyl 40 stearate and polysorbates.

[00130] Subjects affected with or at risk of macular degeneration which are not readily accessible or suitable for ophthalmic (e.g. eye-drops) and/or topical administration, can be treated by a systemic approach, such as intravenous infusion. For example, the primary amine compound can be administered at a low dosage by continuous intravenous infusion. In another example, in which a patient requires longer-term care, the primary amine compound can be administered intermittently (e.g., every 12-24 hours). In a variation of this approach, the initial or loading dose can be followed by maintenance doses that are less than, (e.g., half) the loading dose or by continuous infusion. The duration of such treatment can be determined by those having skill in the art, based on factors, for example, the severity of the condition and the observation of improvements.

[00131] When administering the primary amine compound to the subject by intravenous infusion, devices and equipment (e.g., catheters, such as central or peripheral venous catheters, tubing, drip chambers, flashback bulbs, injection Y sites, stopcocks, and infusion bags) can be used that are compatible with the primary amine compound.

[00132] As discussed above, the primary amine compounds may be administered to a subject in order to treat or prevent macular degeneration and other forms of retinal disease whose etiology involves aberrant all-trans-RAL clearance. Other diseases, disorders, or conditions characterized by aberrant all-trans-RAL may be similarly treated.

[00133] In one embodiment, a subject is diagnosed as having symptoms of macular degeneration, and then a disclosed compound is administered. In another embodiment, a subject may be identified as being at risk for developing macular degeneration (risk factors include a history of smoking, age, female gender, and family history), and then a disclosed compound is administered. In another embodiment, a subject may have dry AMD in both eye, and then a disclosed compound is administered. In another embodiment, a subject may have wet AMD in one eye but dry AMD in the other eye, and then a disclosed compound is administered. In yet
another embodiment, a subject may be diagnosed as having Stargardt disease and then a
disclosed compound is administered. In another embodiment, a subject is diagnosed as having
symptoms of other forms of retinal disease whose etiology involves aberrant all-trans-RAL
clearance, and then the compound is administered. In another embodiment, a subject may be
identified as being at risk for developing other forms of retinal disease whose etiology involves
all-trans-RAL clearance, and then the disclosed compound is administered. In some
embodiments, a compound is administered prophylactically. In some embodiments, a subject
has been diagnosed as having the disease before retinal damage is apparent. In some
embodiments, a human subject may know that he or she is in need of the macular generation
treatment or prevention.

[00134] In some embodiments, a subject may be monitored for the extent of macular
degeneration. A subject may be monitored in a variety of ways, such as by eye examination,
dilated eye examination, fundoscopic examination, visual acuity test, and/or biopsy. Monitoring
can be performed at a variety of times. For example, a subject may be monitored after a
compound is administered. The monitoring can occur, for example, one day, one week, two
weeks, one month, two months, six months, one year, two years, five years, or any other time
period after the first administration of a compound. A subject can be repeatedly monitored. In
some embodiments, the dose of a compound may be altered in response to monitoring.

[00135] In some embodiments, the disclosed methods may be combined with other methods
for treating or preventing macular degeneration or other forms of retinal disease whose etiology
involves aberrant all-trans-RAL clearance, such as photodynamic therapy. For example, a
patient may be treated with more than one therapy for one or more diseases or disorders. For
example, a patient may have one eye afflicted with dry form AMD, which is treated with a
compound of the invention, and the other eye afflicted with wet form AMD, which is treated
with, e.g., photodynamic therapy.

[00136] In yet another aspect, the primary amine compound described herein can be
administered as part of a combinatorial therapy with additional therapeutic agents. The phrase
“combinatorial therapy” or “combination therapy” embraces the administration of a primary
amine compound, and one or more therapeutic agents as part of a specific treatment regimen
intended to provide beneficial effect from the co-action of these therapeutic agents.
Administration of these therapeutic agents in combination typically is carried out over a defined period (usually minutes, hours, days or weeks depending upon the combination selected).
“Combinatorial therapy” or “combination therapy” is intended to embrace administration of these therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example by administering to the subject an individual dose having a fixed ratio of each therapeutic agent or in multiple, individual doses for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissue. The therapeutic agents can be administered by the same route or by different routes. The sequence in which the therapeutic agents are administered is not narrowly critical.

[00137] The invention is further illustrated by the following example, which is not intended to limit the scope of the claims.

**EXAMPLE 1**

**FORMATION OF SCHIFF BASE BETWEEN RETINAL AND SELECTED AMINES**

[00138] We tested 5 FDA approved drugs containing primary amino groups to determine if they react with the aldehyde group of all-\textit{trans}-RAL to form conjugates (Schiff-base) under the physiological conditions of the eye. The five FDA approved drugs included Potaba, Paser, Seromycin, Cuprimine, and Lyrica.

[00139] Formation of conjugates (Schiff-base) between retinal and primary amine compounds containing amino group (putative drugs) is the key mechanism to control all-\textit{trans}-RAL levels in the retina and prevent retina degeneration. Stability of these conjugates is an important factor that can determine biological activity of the drugs. To standardize conditions of Schiff-base formation all reactions were performed in 90% ethanol in water buffered with 0.1 M phosphate buffer, pH 7.0. Stock solution of retinal was made up freshly in ethanol. Its final
concentration was determined spectrophotometrically at 380 nm (ε = 42,880). All procedures were carried out in the dark. Schiff base formation was initiated by addition of retinal stock solution to a 2 molar excess of tested amine dissolved in the reaction buffer. The reaction mixture was incubated for 1 h in room temperature. Steady-state rate of Schiff-base formation was obtained from absorbance changes at 380 and 440 nm (510 nm for aromatic amines) corresponding to free retinal and protonated Schiff base, respectively. To investigate stability of the given retinal conjugates a mixture of HPLC purified Schiff base of selected compound and phosphatidylcholine was dried down in SpeedVac. Then, Schiff-base and lipids were overlaid with 0.1 M phosphate buffer and sonicated immediately to form liposomes. The samples were extracted with hexane following 30 min incubated in room temperature. The breakdown of Schiff-base was monitored by HPLC detection of free retinal extracted from the reaction mixture.

Figs. 3-5 illustrate UV/Vis spectra for the FDA approved drugs. FDA approved drugs that were active readily formed a Schiff base with all-trans-RAL as evidenced by a substantial differential between spectra of unprotonated and protonated Schiff base. Whereas, compounds that were inactive did not readily form a Schiff Base with all-trans-RAL and showed little differential in the spectra. Of the FDA approved drugs tested, Paser, Seromycin, and Lyrica readily formed stable Schiff-bases with all-trans-RAL. In contrast, Potaba and Curprimine did not readily form stable Schiff-bases with all-trans-RAL.

EXAMPLE 2

We tested 20 FDA approved drugs containing primary amino groups to determine if they react with the aldehyde group of all-trans-RAL to reduce its toxic levels in the eye after exposure to light and prevent its condensation into toxic conjugates. The FDA approved drugs included Flumadine, Nameda, Potaba, Dapsone, Paser, Luvox, Seromycin, Aminophippurate Sodium, Cuprimine, Januvia, Primaxin I.M., Prinivil, Sulfamylon, Exforge, Stalevo, Sodium Diuril, Lyrica, Asacol, Tamiflu, or Rilutek. For these experiments, we used ABCA4+/−/RDH8−/− mice as models for Stargardt’s disease and AMD. We employed analytical methods for determining the pharmacodynamics and pharmacokinetics of candidate drugs including: HPLC/MS/MS for analysis of retinoids and histological sections and OCT for assessment of
retinal pathology. The relative amount of retinoids and their composition strongly correlates with the health status of the retina. FDA approved drugs were determined effective in treating retinal degeneration if upon administration to ABCA4<sup>-/-</sup>/RDH8<sup>-/-</sup> mice, the mice showed optical coherence tomography score of at least about 2.5 and the drug increased 11-cis-retinal amount at least about 30% in comparison to untreated control animal. Methodologies for performing the analysis on ABCA4<sup>-/-</sup>/RDH8<sup>-/-</sup> mice is described below.

**ANIMALS**

[R0142] Rdh8<sup>-/-</sup> mice were generated and genotyped as previously described in J. Biol. Chem. 280, 188-18832 (2005). Abca4<sup>-/-</sup> mice also were generated by standard procedures (Ingenious Targeting, Inc., Stony Brook, NY). The targeting vector was constructed by replacing exon 1 with the neo cassette as described by Cell, 98 13-23 (1999). No Immunoreactivity against ABCA4 was detected in eye extracts from these mice by Immunocytochemistry or Immunoblotting. Abca4<sup>-/-</sup> mice were maintained with either pigmented 129SvEv or C57BL/6 mixed backgrounds, and their siblings were used for most experiments. Rdh8<sup>-/-</sup> Abca4<sup>-/-</sup> mice were established by crossbreeding Abca4<sup>-/-</sup> mice with Rdh8<sup>-/-</sup> mice. Genotyping or mice was carried out by PCR with primers ABCR1 (5'-gcccaggttgtgctgtctgctg-3') d ABCR2 (5'-caacagcggcccgcaagc-3') for wild type (WT) (619 bp) and A0 (5'-ccacagcaccaccaattcctcc-3') and N1 (5'-tgccgccccgctgtctgctg-3') for targeted deletion (455 bp). PCR products were cloned and sequenced to verify their identities. Rdh8<sup>-/-</sup> Abca4<sup>-/-</sup> mice were fertile and showed no obvious developmental abnormalities.

**EXTRACTION AND HPLC ANALYSIS OF NON-POLAR RETINOIDS**

[R0143] All experimental procedures related to extraction, derivatization, and separation of retinoids from dissected mouse eyes were carried out under dim red light. Two whole mouse eyes were homogenized in 1 ml of 50 mM phosphate buffer, pH 7.0, containing 50% ethanol and 10 mM NH<sub>4</sub>OH. Ice-cold methanol (1 ml) was added to the homogenates 20 min after incubation at room temperature (RT), non-polar retinoids were extracted twice with 4 ml of hexane. The organic phase was collected, dried down in a SpeedVac and re-solubilized in 0.3 ml of hexane. Three main classes of retinoids (retinyl esters, retinal oximes, and retinols) as well as
their geometrical isomers was separated in single run by normal phase HPLC by using an Agilent Si, 5 μm, 4.5 x 250 mm column and a stepwise gradient of ethylacetate in hexane (0.5% for 15 min, and 6% for up to 60 min) at a flow rate of 1.4 ml/min (Fig. 6). Retinoids were detected at 325 nm (retinyl esters and retinols) and 350 nm (retinyl oximes) with a diode array detector. Those of interest were quantified based on the areas under their peaks calculated with the help of HP Chemstation A.03.03 software and compared with areas calculated based on known amounts of synthetic standards plotted as a standard curve.

MASS SPECTROMETRY OF RETINOIDS

[00144] A complementary technique, mass spectrometry, was used to detect, identify, and quantify retinoids and their derivatives in eye tissue. The conjugated polyene chain of retinoids contributes to relatively strong light absorption at UV and visible wavelengths. Thus, absorbance spectra provided information about the number of conjugated double bonds. Moreover, slight differences in wavelengths of maximum absorbance and shapes of the spectra permitted precise identification of retinoid isomers. However, a limitation of this method is the low selectivity of its UV–Vis absorbance, which mandates carefully designed chromatographic conditions and precise identification of the compounds being analyzed. This analysis can become especially challenging when multiple geometric isomers of retinoids at low abundance (less than 3 pmols/eye) or unidentified compounds are present. Thus, we used an alternative technique, mass spectrometry combined with high performance liquid chromatography (LC–MS) to address this issue. Mass spectra of retinoids was acquired by using a LXQ high throughput linear ion trap mass spectrometer (Thermo Scientific, Waltham, MA) connected with an Agilent 1100 HPLC system and interfaced with an atmospheric pressure chemical ionization (APCI) source. The APCI source in a positive ionization mode is chosen for LC–MS methodology because of its wide dynamic range and capacity to operate at the high flow rates required for HPLC retinoid separation. The greatest advantage of LC–MS is its sensitivity that reaches the limits of retinoid detection and quantification in the 10 to 50 fmol and 20 to 200 fmol ranges, respectively. Moreover, this LXQ instrument has capability to perform MSn analyses that provide definitive structural identification.
DETECTION AND QUANTIFICATION OF RETINAL AMINE CONDENSATION PRODUCTS IN MOUSE EYE

[00145] Eyes of mice treated with compounds containing primary amines were homogenized in Tris/HCl buffer, pH 9.0, in 50% methanol and extracted with hexane or ethyl acetate depending of the polarity, dried down and resuspended in acetonitrile. After centrifugation, extracted compounds in the supernatant were separated by reverse phase HPLC chromatography (Agilent Zorbax Eclipse XBD C18, 5 μm, 4.6 x 150 mm column) with a linear gradient of water in acetonitrile (50 – 100%) for 20 min at a fixed flow rate of 1.5 ml/min. Retinal conjugates were detected and identified with a LXQ mass spectrometer equipped with an APCI source. MS scans were recorded in a SIM mode for each individual compound (Fig. 7 M3). The identity of detected adducts will be confirmed based on their MS² spectra. Amounts of retinal–amine conjugates will be quantified with the aid of isotopically labeled synthetic standards added prior to extraction.

ULTRA-HIGH RESOLUTION SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY (SD-OCT) IMAGING

[00146] Although analytical and histological methods provide exhaustive characterization of retina, they cannot be performed in vivo. To reduce the number of sacrificed animals and time required for analysis, SD-OCT from Bioptigen (Research Triangle Park, NC) was employed for in vivo imaging of mouse retinas. Bioptigen OCT systems utilize a narrow single-mode beam from a wide bandwidth light source to probe the structure of retina at a higher resolution (2.0 μm) than normal OCT systems. Mice were anesthetized by intraperitoneal (IP) injection of 20 μl/g bw of 6 mg/ml ketamine and 0.44 mg/ml xylazine diluted with 10 mM sodium phosphate, pH 7.2, containing 100 mM NaCl. Pupils were dilated with 1% tropicamide. In vivo SD–OCT images were obtained from both eyes. Four pictures acquired in a B-scan mode were used to construct the final averaged images (Fig. 8). SD-OCT imaging enabled us to identify early pathological changes in the retina and monitor progression or amelioration/prevention of pathological lesions quantitatively under various therapeutic regimens in the same live animal at a resolution comparable to that obtained by current histopathological methods that employ cross sections of the retina.
GRADING WITH OCT

[00147] In vivo retinal structures of Rdh8<sup>−/−</sup> Abca4<sup>−/−</sup> mice are imaged by SD-OCT 7 days after 10,000 lux illumination for 30 min at 4 weeks of age. Fig. 9 illustrates Rdh8<sup>−/−</sup> Abca4<sup>−/−</sup> mouse without light shows healthy retina, whereas light with 10,000 lux for 30 min cause severe retinal degeneration (left panel). Preventive effects of compounds in retinal morphology are indicated as OCT score (right panel).

Score 5: no retinal degeneration
Score 4: regional retinal degeneration (less than 1000 μm width)
Score 3: widely observed retinal degeneration (more than 1000 μm width) with reflection of ELM
Score 2: widely observed retinal degeneration (more than 1000 μm width) without reflection of ELM
Score 1: severe retinal degeneration without reflection from photoreceptors as well as light exposed Rdh8<sup>−/−</sup> Abca4<sup>−/−</sup> mice (see left panel)

RESULTS

[00148] The following Table lists the OCT score and 11 cis-retinal area of ABCA4<sup>−/−</sup>/RDH8<sup>−/−</sup> treated with Flumadine, Nameda, Potaba, Dapsone, Paser, Luvox, Seromycin, Aminohippurate Sodium, Cuprimine, Januvia, Primaxin I.M., Prinivil, Sulfamylon, Exforge, Stalevo, Sodium Diuril, Lyrica, Asacol, Tamiflu, or Rilutek. As noted in the Table, ABCA4<sup>−/−</sup>/RDH8<sup>−/−</sup> mice treated with either Flumadine, Dapsone, Paser, Luvox, Seromycin, Januvia, Sulfamylon, Exforge, Sodium Diuril, Lyrica, Asacol, or Rilutek had a optical coherence tomography score of at least about 2.5 and the drug increased 11-cis-retinal amount at least about 30% in comparison to untreated control animal and were effective in treating retinal degeneration in the mice. It is noted that the three FDA approved drugs that readily formed Schiff bases in Example 1 with all-trans-RAL under simulated physiological conditions had a optical coherence tomography score of at least about 2.5, increased 11-cis-retinal amount at least about 30% in comparison to untreated control animal, and were effective in treating retinal degeneration in the mice. In contrast, the two FDA approved drugs that did not readily formed Schiff bases in Example 1
with all-trans-RAL under simulated physiological conditions had an optical coherence
tomography score below 2.5, did not increase 11-cis-retinal amount at least about 30% in
comparison to untreated control animal, and were ineffective in treating retinal degeneration in
the mice.

<table>
<thead>
<tr>
<th></th>
<th>Score OCT</th>
<th>11cRAL (area)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Flumadine</td>
<td>6.5</td>
</tr>
<tr>
<td>2</td>
<td>Nameda</td>
<td>1.7</td>
</tr>
<tr>
<td>3</td>
<td>Potaba</td>
<td>2.3</td>
</tr>
<tr>
<td>4</td>
<td>Dapsone</td>
<td>2.5</td>
</tr>
<tr>
<td>5</td>
<td>Paser</td>
<td>151.9</td>
</tr>
<tr>
<td>6</td>
<td>Luvox</td>
<td>175.5</td>
</tr>
<tr>
<td>7</td>
<td>Seromycin</td>
<td>159.9</td>
</tr>
<tr>
<td>8</td>
<td>Aminohippurate Sodium</td>
<td>109.4</td>
</tr>
<tr>
<td>9</td>
<td>Cuprimine</td>
<td>1.7</td>
</tr>
<tr>
<td>10</td>
<td>Januvia</td>
<td>2.5</td>
</tr>
<tr>
<td>11</td>
<td>Primaxin I.M.</td>
<td>108.1</td>
</tr>
<tr>
<td>12</td>
<td>Prinivil</td>
<td>2.0</td>
</tr>
<tr>
<td>13</td>
<td>Sulfamylon</td>
<td>2.5</td>
</tr>
<tr>
<td>14</td>
<td>Exforge</td>
<td>166.1</td>
</tr>
<tr>
<td>15</td>
<td>Stalevo</td>
<td>86.7</td>
</tr>
<tr>
<td>16</td>
<td>Sodium Diuril</td>
<td>139.7</td>
</tr>
<tr>
<td>17</td>
<td>Lyrica</td>
<td>166.5</td>
</tr>
<tr>
<td>18</td>
<td>Asacol</td>
<td>140.2</td>
</tr>
<tr>
<td>19</td>
<td>Tamiflu</td>
<td>1.3</td>
</tr>
<tr>
<td>20</td>
<td>Rilutek</td>
<td>158.2</td>
</tr>
<tr>
<td>21</td>
<td>No Treatment</td>
<td>188.2</td>
</tr>
</tbody>
</table>
Having described the invention, the following is claimed:

1. A method of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina, the method comprising:

   administering to the subject a therapeutically effective amount of a primary amine compound of formula:

   \[
   \text{R}_1 \text{NH}_2
   \]

   wherein R\(_1\) is an aliphatic and/or aromatic compound; the primary amine compound upon administration to the subject forming a reversible Schiff-base with the all-trans-retinal without adversely affecting normal retinoid cycle performance; the primary amine compound when administered to a Rdh8\(^{-}\)/Abca4\(^{-}\) mouse increasing the optical coherence tomography score of the mouse to at least about 2.5 and increasing 11-cis-retinal amount at least about 30% in comparison to untreated control animal, wherein the primary amine compound is not a local anesthetic, which includes an aromatic amine, that demonstrates sodium channel blockade when administered to the subject.

2. The method of claim 1, the primary amine compound not inhibiting RPE65 enzymatic activity or any other proteins involved in retinoid metabolism in the eye of the subject.

3. The method of claim 2, the primary amine compounds reducing the formation of A2E and/or retinal dimer in the subject’s retina.

4. The method of claim 1, the primary amine compound promoting 11-cis-retinal production in the subject.

5. The method of claim 1, the primary amine compound being delivered to the subject by at least one of topical administration, systemic administration, intravitreal injection, and intraocular delivery.
6. The method of claim 1, the primary amine being provided in an ocular preparation for sustained delivery.

7. The method of claim 1, the ocular disorder comprising at least one of macular degeneration, Stargardt’s disease, and retinitis pigmentosa.

8. The method of claim 1, the primary amine compound not causing night blindness in the subject.

9. The method of claim 1, wherein $R_1$ is an aliphatic compound.

10. The method of claim 1, wherein $R_1$ is an aromatic compound.

11. The method of claim 1, the primary compound comprising the formula:
wherein $R_2$ is hydrogen or (C$_1$-C$_6$) straight chain or branched unsubstituted or substituted alkyl;

$R_3$ is straight or branched unsubstituted or substituted alkyl of from 1 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylecycloalkyl, -alkylalkoxy, -alkyl, OH, -alkylphenyl, -alkylphenoxy, -phenyl or substituted phenyl;

$R_4$ is hydrogen or (C$_1$-C$_6$) straight chain or branched unsubstituted or substituted alkyl, or carboxyl;

$\text{Ar}$ is phenyl which is unsubstituted or substituted with 1-5 of $R_7$, wherein $R_7$ is independently selected from the group consisting of:

(1) halogen,
(2) C<sub>1-6</sub> alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens,

(3) OC<sub>1-6</sub> alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens, and

(4) CN;

X<sub>1</sub> is selected from the group consisting of:

(1) N, and

(2) CR<sub>6</sub>;

R<sub>5</sub> and R<sub>6</sub> are independently selected from the group consisting of:

(1) hydrogen,

(2) CN,

(3) C<sub>1-10</sub> alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 halogens or phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R<sub>8</sub>, OR<sub>8</sub>, NHSO<sub>2</sub>R<sub>8</sub>, SO<sub>2</sub>R<sub>8</sub>, CO<sub>2</sub>H, and CO<sub>2</sub>C<sub>1-6</sub> alkyl, wherein the CO<sub>2</sub>C<sub>1-6</sub> alkyl is linear or branched,

(4) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R<sub>8</sub>, OR<sub>8</sub>, NHSO<sub>2</sub>R<sub>8</sub>, SO<sub>2</sub>R<sub>8</sub>, CO<sub>2</sub>H, and CO<sub>2</sub>C<sub>1-6</sub> alkyl, wherein the CO<sub>2</sub>C<sub>1-6</sub> alkyl is linear or branched, and

(5) a 5- or 6-membered heterocycle which may be saturated or unsaturated comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being unsubstituted or substituted with 1-3 substituents independently selected from oxo, OH, halogen, C<sub>1-6</sub> alkyl, and OC<sub>1-6</sub> alkyl, wherein the C<sub>1-6</sub> alkyl and OC<sub>1-6</sub> alkyl are linear or branched and optionally substituted with 1-5 halogens;

R<sub>8</sub> is C<sub>1-6</sub> alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 groups independently selected from halogen, CO<sub>2</sub>H, and CO<sub>2</sub>C<sub>1-6</sub> alkyl, wherein the CO<sub>2</sub>C<sub>1-6</sub> alkyl is linear or branched;

R<sub>9</sub> and R<sub>10</sub> may be the same or different and are hydrogen, straight or branched alkyl of from one to six carbon atoms, lower alkyaryl, lower alkenyl, phenyl, CF<sub>3</sub>, hydroxy, lower alkoxy, lower alkylthio, lower alkylsulphonyl, CF<sub>3</sub>O, at the six position halogen, nitro,
carboxy, lower alkoxy carbonyl, NR_{11}R_{12}CO, NR_{11}R_{12}, R_{11}CONR_{12}, CN, NR_{11}R_{12}SO_{2}, wherein R_{11} and R_{12} may be the same or different and are hydrogen, lower alkyl, or aryl; R_9 and R_{10} may together form a carbocyclic or methylenedioxy ring;

R_{14} is cyano, cyanomethyl, methoxymethyl, or ethoxymethyl;

X_2 is O, N(H), or S, het is a 5 or 6-membered heterocycle, n is 0, 1, 2, or 3, and each D is an unbranched lower alkyl group;

U is a substituent selected from halogen atom; cyano; lower alkyl wherein one or more hydrogen atoms on the lower alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms; lower alky thio wherein one or more hydrogen atoms on the alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl; lower alkyl sulfon yl wherein one or more hydrogen atoms on the alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl; hydroxyl; lower alkoxy; formyl; lower alkyl carbonyl; aryl carbonyl; carboxyl; lower alkoxy carbonyl; carbamoyl; N-lower alkyl carbamoyl; N,N-di-lower alkylaminocarbonyl; amino; N-lower alkyl am ino; N,N-di-lower alkylamino; formylamino; lower alkyl carbamoyl amino; aminosulfon ylamino; (N-lower alkylamino)sulfon ylamino; (N,N-di-lower alkylamino)sulfon ylamino; aryl, optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, aryl and amino; and a monocyclic or bicyclic heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms;

W, X, Y, and Z are each, independently, N, S, O, CU or CH, such that at least one of W, X, Y, and Z is N;

A is

\[
\begin{align*}
&\text{D is unbranched lower alkyl;} \\
&\text{or}
\end{align*}
\]
R_{15} and R_{16} are each independently substituted or unsubstituted C_{1}, C_{2}, C_{3}, C_{4}, C_{5}, C_{6}, C_{7}, or C_{8}, straight chain alkyl, or substituted or unsubstituted C_{3}, C_{4}, C_{5}, C_{6}, C_{7}, or C_{8}, branched chain alkyl;

L is a single bond or CH_{2};

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

Y_{1} is --(CH_{2})_{2}-- , --(CH_{2})_{3}-- , --CH_{2} CH(CH_{3})-- or --CH_{2} C(CH_{3})--;

R_{17} is aryl or heteroaryl;

R_{18} and R_{19} are each independently C_{1} -C_{4} alkyl or 2-methoxyethyl;

R_{20} is hydrogen, C_{1} -C_{4} alkyl, 2-(C_{1} -C_{4} alkoxy)ethyl, cyclopropylmethyl, benzyl, or --(CH_{2})_{m1}COR_{21} where m1 is 1, 2 or 3 and R_{21} is hydroxy, C_{1} -C_{4} alkoxy or --NR_{22} where R_{22} hydrogen or C_{1} -C_{4} alkyl;

R_{23} and R_{24} can be the same or different and are hydrogen, methyl, or ethyl as well as pharmaceutically acceptable salts thereof.

12. The method of claim 1, the primary amine compound being selected from the group consisting of:

\[
\text{\begin{align*}
&\text{NH}_{2} \\
&\text{;}
\end{align*}}
\]

\[
\text{\begin{align*}
&\text{H}_{2}\text{N} \\
&\text{\;}
\end{align*}}
\]

\[
\text{\begin{align*}
&\text{SO} \\
&\text{;}
\end{align*}}
\]

\[
\text{\begin{align*}
&\text{NH}_{2} \\
&\text{;}
\end{align*}}
\]
and pharmaceutically acceptable salts thereof.
13. The method of claim 1, wherein the primary amine compound is selected from the group consisting of:

- Chemical structures of the primary amine compounds.
14. A method of treating a retinal pathology in a subject associated with aberrant all-trans-retinal clearance in the retina outer segment, the method comprising:

administering to the subject a therapeutically effective amount of a primary amine compound of formula:

\[
\text{R}_1 \text{NH}_2
\]

wherein \text{R}_1 is an aliphatic and/or aromatic compound; the primary amine compound upon administration to the subject forming a reversible Schiff-base with the all-trans-retinal without adversely affecting normal retinoid cycle performance; the primary amine compound when administered to a Rdh8\textsuperscript{+/+}Abca4\textsuperscript{+/+} mouse increasing the optical coherence tomography score of the mouse to at least about 2.5 and increasing 11-cis-retinal amount at least about 30% in comparison to untreated control animal, wherein the primary amine compound is not a local anesthetic, which includes an aromatic amine, that demonstrates sodium channel blockade when administered to the subject.
15. The method of claim 14, the primary amine compound not inhibiting RPE65 enzymatic activity or any other proteins involved in retinoid metabolism in the eye of the subject.

16. The method of claim 15, the primary amine compounds reducing the formation of A2E and/or retinal dimer in the subject’s retina.

17. The method of claim 14, the primary amine compound promoting 11-cis-retinal production in the subject.

18. The method of claim 14, the primary amine compound being delivered to the subject by at least one of topical administration, systemic administration, intravitreal injection, and intraocular delivery.

19. The method of claim 14, the primary amine being provided in an ocular preparation for sustained delivery.

20. The method of claim 14, the retinal pathology comprising at least one of macular degeneration, Stargardt’s disease, and retinitis pigmentosa.

21. The method of claim 14, the primary amine compound not causing night blindness in the subject.

22. The method of claim 14, wherein \( R_1 \) is an aliphatic compound.

23. The method of claim 14, wherein \( R_1 \) is an aromatic compound.

24. The method of claim 14, wherein the primary amine compound is selected from the group consisting of:
25. The method of claim 14, the primary compound comprising the formula:
wherein \( R_2 \) is hydrogen or \((C_1-C_6)\) straight chain or branched unsubstituted or substituted alkyl;

\( R_3 \) is straight or branched unsubstituted or substituted alkyl of from 1 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, \(-\text{alkylcycloalkyl}\), \(-\text{alkylalkoxy}\), \(-\text{alkyl}\), \(-\text{OH}\), \(-\text{alkylphenyl}\), \(-\text{alkylphenoxy}\), \(-\text{phenyl or substituted phenyl}\);

\( R_4 \) is hydrogen or \((C_1-C_6)\) straight chain or branched unsubstituted or substituted alkyl, or carboxyl;

\( Ar \) is phenyl which is unsubstituted or substituted with 1-5 of \( R_7 \), wherein \( R_7 \) is independently selected from the group consisting of:

1. halogen,
2. \( C_{1-6} \) alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens,
3. \( OC_{1-6} \) alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens, and
4. CN;

\( X_1 \) is selected from the group consisting of:

1. N, and
2. CR\(_6\);

\( R_5 \) and \( R_6 \) are independently selected from the group consisting of:

1. hydrogen,
2. CN,
(3) C\textsubscript{1-10} alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 halogens or phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R\textsubscript{8}, OR\textsubscript{8}, NH\textsubscript{2}SO\textsubscript{2} R\textsubscript{8}, SO\textsubscript{2} R\textsubscript{8}, CO\textsubscript{2} H, and CO\textsubscript{2} C\textsubscript{1-6} alkyl, wherein the CO\textsubscript{2} C\textsubscript{1-6} alkyl is linear or branched,

(4) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R\textsubscript{8}, OR\textsubscript{8}, NH\textsubscript{2}SO\textsubscript{2} R\textsubscript{8}, SO\textsubscript{2} R\textsubscript{8}, CO\textsubscript{2} H, and CO\textsubscript{2} C\textsubscript{1-6} alkyl, wherein the CO\textsubscript{2} C\textsubscript{1-6} alkyl is linear or branched, and

(5) a 5- or 6-membered heterocycle which may be saturated or unsaturated comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being unsubstituted or substituted with 1-3 substituents independently selected from oxo, OH, halogen, C\textsubscript{1-6} alkyl, and OC\textsubscript{1-6} alkyl, wherein the C\textsubscript{1-6} alkyl and OC\textsubscript{1-6} alkyl are linear or branched and optionally substituted with 1-5 halogens;

R\textsubscript{8} is C\textsubscript{1-6} alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 groups independently selected from halogen, CO\textsubscript{2} H, and CO\textsubscript{2} C\textsubscript{1-6} alkyl, wherein the CO\textsubscript{2} C\textsubscript{1-6} alkyl is linear or branched;

R\textsubscript{9} and R\textsubscript{10} may be the same or different and are hydrogen, straight or branched alkyl of from one to six carbon atoms, lower alkyaryl, lower alkenyl, phenyl, CF\textsubscript{3}, hydroxy, lower alkoxy, lower alkylthio, lower alkylsulphonyl, CF\textsubscript{3} O, at the six position halogen, nitro, carboxy, lower alkoxycarbonyl, NR\textsubscript{11}R\textsubscript{12}CO, NR\textsubscript{11}R\textsubscript{12}, R\textsubscript{11}CONR\textsubscript{12}, CN, NR\textsubscript{11}R\textsubscript{12}SO\textsubscript{2}, wherein R\textsubscript{11} and R\textsubscript{12} may be the same or different and are hydrogen, lower alkyl, or aryl; R\textsubscript{9} and R\textsubscript{10} may together form a carbocyclic or methylenedioxy ring;

R\textsubscript{14} is cyano, cyanomethyl, methoxymethyl, or ethoxymethyl;

X\textsubscript{2} is O, N(H), or S, het is a 5 or 6-membered heterocycle, n is 0, 1, 2, or 3, and each D is an unbranched lower alkyl group;

U is a substituent selected from halogen atom; cyano; lower alkyl wherein one or more hydrogen atoms on the lower alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms; lower alkylthio wherein one or more hydrogen atoms on the alkyl group are
optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl; lower alkylsulfonyl wherein one or more hydrogen atoms on the alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxy carbonyl; carbamoyl; N-lower alkyl carbamoyl; N,N-di-lower alkylaminocarbonyl; amino; N-lower alkyl ammino; N,N-di-lower alkyl ammino; formyl ammino; lower alkyl carbonylamino; aminosulfonylamino; (N-lower alkyl ammino)sulfonylamino; (N,N-di-lower alkyl ammino)sulfonylamino; aryl, optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, aryl and amino; and a monocyclic or bicyclic heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms;

W, X, Y, and Z are each, independently, N, S, O CU or CH, such that at least one of W, X, Y, and Z is N;

A is

\[
\begin{align*}
\text{D is unbranched lower alkyl;} \\
\text{R}_{15} \text{ and } \text{R}_{16} \text{ are each independently substituted or unsubstituted } C_1, C_2, C_3, C_4, C_5, \\
C_6, C_7, \text{ or } C_8, \text{ straight chain alkyl, or substituted or unsubstituted } C_3, C_4, C_5, C_6, C_7, \text{ or } C_8, \\
\text{branched chain alkyl;} \\
\text{L is a single bond or } CH_2; \\
\text{m is } 0, 1, \text{ or } 2; \\
\text{n is } 0, 1, 2, 3, \text{ or } 4; \\
Y_1 \text{ is } \text{--(CH}_2\text{)}_2 \text{ --, --(CH}_3\text{)}_3 \text{ --, --CH}_2\text{CH(CH}_3\text{)}\_\text{-- or --CH}_2\text{C(CH}_3\text{)}_2 \text{--;} \\
\text{R}_{17} \text{ is aryl or heteroaryl;} \\
\text{R}_{18} \text{ and } \text{R}_{19} \text{ are each independently } C_1 -C_4 \text{ alkyl or 2-methoxyethyl;} \\
\text{R}_{20} \text{ is hydrogen, } C_1 -C_4 \text{ alkyl, 2-}(C_1 -C_4 \text{ alkoxy})\text{ethyl, cyclopropylmethyl, benzyl,} \\
\text{or } \text{--(CH}_2\text{)}_m\text{COR}_{21} \text{ where } m \text{ is } 1, 2 \text{ or } 3 \text{ and } R_{21} \text{ is hydroxy, } C_1 -C_4 \text{ alkoxy or } -NR_22 \text{ where } R_{22} \text{ hydrogen or } C_1 -C_4 \text{ alkyl;} 
\end{align*}
\]
$R_{23}$ and $R_{24}$ can be the same or different and are hydrogen, methyl, or ethyl as well as pharmaceutically acceptable salts thereof.

26. The method of claim 14, the primary amine compound being selected from the group consisting of:

\[ \text{Diagram images of chemical structures} \]
and pharmaceutically acceptable salts thereof.

27. The method of claim 14, wherein the primary amine compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
28. A method of treating Stargardt’s disease in a subject, the method comprising: administering to the subject a therapeutically effective amount of a primary amine compound of formula:

\[
\begin{array}{c}
R_1 \\
\text{NH}_2
\end{array}
\]

wherein \( R_1 \) is an aliphatic and/or aromatic compound; the primary amine compound upon administration to the subject forming a reversible Schiff-base with the all-\textit{trans}-retinal without adversely affecting normal retinoid cycle performance; the primary amine compound when administered to a Rdh8\textsuperscript{−/−}Abca4\textsuperscript{−/−} mouse increasing the optical coherence tomography score of the mouse to at least about 2.5 and increasing 11-cis-retinal amount at least about 30% in comparison to untreated control animal, wherein the primary amine compound is not a local anesthetic, which includes an aromatic amine, that demonstrates sodium channel blockade when administered to the subject.

29. The method of claim 28, the primary amine compound not inhibiting RPE65 enzymatic activity or any other proteins involved in retinoid metabolism in the eye of the subject.

30. The method of claim 29, the primary amine compounds reducing the formation of A2E and/or retinal dimer in the subject’s retina.

31. The method of claim 28, the primary amine compound promoting 11-cis-retinal production in the subject.

32. The method of claim 28, the primary amine compound being delivered to the subject by at least one of topical administration, systemic administration, intravitreal injection, and intraocular delivery.

33. The method of claim 28, the primary amine being provided in an ocular preparation for sustained delivery.
34. The method of claim 28, the primary amine compound not causing night blindness in the subject.

35. The method of claim 28, wherein \( R_1 \) is an aliphatic compound.

36. The method of claim 28, wherein \( R_1 \) is an aromatic compound.

37. The method of claim 28, wherein the primary amine compound is selected from the group consisting of:

38. The method of claim 28, the primary compound comprising the formula:
wherein $R_2$ is hydrogen or $(C_1-C_6)$ straight chain or branched unsubstituted or substituted alkyl;

$R_3$ is straight or branched unsubstituted or substituted alkyl of from 1 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylecycloalkyl, -alkylalkoxy, -alkyl, OH, -alkylphenyl, -alkylphenoxy, -phenyl or substituted phenyl;

$R_4$ is hydrogen or $(C_1-C_6)$ straight chain or branched unsubstituted or substituted alkyl, or carboxyl;

$Ar$ is phenyl which is unsubstituted or substituted with 1-5 of $R_7$, wherein $R_7$ is independently selected from the group consisting of:

(1) halogen,
(2) **C\textsubscript{1-6} alkyl**, which is linear or branched and is unsubstituted or substituted with 1-5 halogens, 

(3) **OC\textsubscript{1-6} alkyl**, which is linear or branched and is unsubstituted or substituted with 1-5 halogens, and

(4) **CN**;

\( X_1 \) is selected from the group consisting of:

(1) N, and

(2) **CR\textsubscript{6}**;

\( R_5 \) and \( R_6 \) are independently selected from the group consisting of:

(1) hydrogen,

(2) **CN**,

(3) **C\textsubscript{1-10} alkyl**, which is linear or branched and which is unsubstituted or substituted with 1-5 halogens or phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R\textsubscript{8}, OR\textsubscript{8}, NHSO\textsubscript{2} R\textsubscript{8}, SO\textsubscript{2} R\textsubscript{8}, CO\textsubscript{2} H, and CO\textsubscript{2} C\textsubscript{1-6} alkyl, wherein the CO\textsubscript{2} C\textsubscript{1-6} alkyl is linear or branched,

(4) **phenyl** which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R\textsubscript{8}, OR\textsubscript{8}, NHSO\textsubscript{2} R\textsubscript{8}, SO\textsubscript{2} R\textsubscript{8}, CO\textsubscript{2} H, and CO\textsubscript{2} C\textsubscript{1-6} alkyl, wherein the CO\textsubscript{2} C\textsubscript{1-6} alkyl is linear or branched, and

(5) a 5- or 6-membered heterocycle which may be saturated or unsaturated comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being unsubstituted or substituted with 1-3 substituents independently selected from oxo, OH, halogen, C\textsubscript{1-6} alkyl, and OC\textsubscript{1-6} alkyl, wherein the C\textsubscript{1-6} alkyl and OC\textsubscript{1-6} alkyl are linear or branched and optionally substituted with 1-5 halogens;

\( R_8 \) is **C\textsubscript{1-6} alkyl**, which is linear or branched and which is unsubstituted or substituted with 1-5 groups independently selected from halogen, CO\textsubscript{2} H, and CO\textsubscript{2} C\textsubscript{1-6} alkyl, wherein the CO\textsubscript{2} C\textsubscript{1-6} alkyl is linear or branched;

\( R_9 \) and \( R_{10} \) may be the same or different and are hydrogen, straight or branched alkyl of from one to six carbon atoms, lower alkyllaryl, lower alkenyl, phenyl, CF\textsubscript{3}, hydroxy, lower alkoxy, lower alkylthio, lower alkylsulphonyl, CF\textsubscript{3} O, at the six position halogen, nitro,
carboxy, lower alkoxy carbonyl, NR_{11}R_{12}CO, NR_{11}R_{12}, R_{11}CONR_{12}, CN, NR_{11}R_{12}SO_{2}, wherein
R_{11} and R_{12} may be the same or different and are hydrogen, lower alkyl, or aryl; R_9 and R_{10} may
together form a carbocyclic or methylendioxy ring;
R_{14} is cyano, cyanomethyl, methoxymethyl, or ethoxymethyl;
X_2 is O, N(H), or S, het is a 5 or 6-membered heterocycle, n is 0, 1, 2, or 3, and
each D is an unbranched lower alkyl group;
U is a substituent selected from halogen atom; cyano; lower alkyl wherein one or
more hydrogen atoms on the lower alkyl group are optionally substituted by groups selected
from a halogen atom, hydroxyl, carbamoyl, amino, and a monocyclic or bicyclic
heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and
sulfur atoms; lower alkylthio wherein one or more hydrogen atoms on the alkyl group are
optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and
aryl; lower alkyl sulfonyl wherein one or more hydrogen atoms on the alkyl group are optionally
substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl;
hydroxy; lower alkoxy; formyl; lower alkyl carbonyl; aryl carbonyl; carboxyl; lower
alkoxy carbonyl; carbamoyl; N-lower alkyl carbamoyl; N,N-di-lower alkylaminocarbonyl; amino;
N-lower alkyl amino; N,N-di-lower alkyl amino; formyl amino; lower alkyl carbonylamino;
aminosulfonylamino; (N-lower alkyl amino) sulfonylamino; (N,N-di-lower
alkyl amino) sulfonylamino; aryl, optionally substituted by groups selected from a halogen atom,
hydroxyl, carbamoyl, aryl and amino; and a monocyclic or bicyclic heterocyclic group
containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms;
W, X, Y, and Z are each, independently, N, S, O CU or CH, such that at least one
of W, X, Y, and Z is N;

A is

\[ \text{D is unbranched lower alkyl;} \]
R₁₅ and R₁₆ are each independently substituted or unsubstituted C₁, C₂, C₃, C₄, C₅, C₆, C₇, or C₈, straight chain alkyl, or substituted or unsubstituted C₃, C₄, C₅, C₆, C₇, or C₈, branched chain alkyl;

L is a single bond or CH₂;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

Y₁ is --(CH₂)₂ --, --(CH₃)₂ --, --CH₂ CH(CH₃)₂ or --CH₂ C(CH₃)₂ --;

R₁₇ is aryl or heteroaryl;

R₁₈ and R₁₉ are each independently C₁ -C₄ alkyl or 2-methoxyethyl;

R₂₀ is hydrogen, C₁ -C₄ alkyl, 2-(C₁ -C₄ alkoxy)ethyl, cyclopropylmethyl, benzyl, or --(CH₂)ₘ₁ COR₂₁ where m₁ is 1, 2 or 3 and R₂₁ is hydroxy, C₁ -C₄ alkoxy or --NR₂₂ where R₂₂ hydrogen or C₁ -C₄ alkyl;

R₂₃ and R₂₄ can be the same or different and are hydrogen, methyl, or ethyl as well as pharmaceutically acceptable salts thereof.

39. The method of claim 28, the primary amine compound being selected from the group consisting of:

\[ \text{NH}_2 \]

\[ \text{CH}_3 \]

\[ \text{S}\text{O} \]

\[ \text{H}_2\text{N} \]

\[ \text{NH}_2 \]
and pharmaceutically acceptable salts thereof.
40. The method of claim 28, wherein the primary amine compound is selected from the group consisting of:

![Chemical structures representing various compounds with different functional groups and substituents.](image-url)
and pharmaceutically acceptable salts thereof.

41. A method of treating macular degeneration in a subject, the method comprising: administering to the subject a therapeutically effective amount of a primary amine compound of formula:

![Chemical Structure](image)

\( R_1 \stackrel{\text{NH}_2}{\text{NH}} \)

wherein \( R_1 \) is an aliphatic and/or aromatic compound; the primary amine compound upon administration to the subject forming a reversible Schiff-base with the \( \text{all-trans} \)-retinal without adversely affecting normal retinoid cycle performance; the primary amine compound when administered to a \( \text{Rdh8}^{+/-}\text{Abca4}^{+/-} \) mouse increasing the optical coherence tomography score of the mouse to at least about 2.5 and increasing \( 11\text{-cis} \)-retinal amount at least about 30% in comparison to untreated control animal, wherein the primary amine compound is not a local anesthetic, which includes an aromatic amine, that demonstrates sodium channel blockade when administered to the subject.
42. The method of claim 41, the primary amine compound not inhibiting RPE65 enzymatic activity or any other proteins involved in retinoid metabolism in the eye of the subject.

43. The method of claim 42, the primary amine compounds reducing the formation of A2E and/or retinal dimer in the subject’s retina.

44. The method of claim 41, the primary amine compound promoting 11-cis-retinal production in the subject.

45. The method of claim 41, the primary amine compound being delivered to the subject by at least one of topical administration, systemic administration, intravitreal injection, and intraocular delivery.

46. The method of claim 41, the primary amine being provided in an ocular preparation for sustained delivery.

47. The method of claim 41, the primary amine compound not causing night blindness in the subject.

48. The method of claim 41, wherein R₁ is an aliphatic compound.

49. The method of claim 41, wherein R₁ is an aromatic compound.

50. The method of claim 41, wherein the primary amine compound is selected from the group consisting of:
51. The method of claim 41, the primary compound comprising the formula:
wherein $R_2$ is hydrogen or (C$_1$-C$_6$) straight chain or branched unsubstituted or substituted alkyl;

$R_3$ is straight or branched unsubstituted or substituted alkyl of from 1 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkycycloalkyl, -alkylalkoxy, -alkyl, OH, -alkylphenyl, -alkylphenoxy, -phenyl or substituted phenyl;

$R_4$ is hydrogen or (C$_1$-C$_6$) straight chain or branched unsubstituted or substituted alkyl, or carboxyl;

$Ar$ is phenyl which is unsubstituted or substituted with 1-5 of $R_7$, wherein $R_7$ is independently selected from the group consisting of:

1. halogen,
2. C$_{1-6}$ alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens,
3. OC$_{1-6}$ alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens, and
4. CN;

$X_1$ is selected from the group consisting of:

1. N, and
2. CR$_6$;

$R_5$ and $R_6$ are independently selected from the group consisting of:

1. hydrogen,
2. CN,
(3) C_{1-10} alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 halogens or phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R_{8,}, OR_{8,}, NHSO_{2} R_{8,}, SO_{2} R_{8,}, CO_{2} H, and CO_{2} C_{1-6} alkyl, wherein the CO_{2} C_{1-6} alkyl is linear or branched,

(4) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R_{8,}, OR_{8,}, NHSO_{2} R_{8,}, SO_{2} R_{8,}, CO_{2} H, and CO_{2} C_{1-6} alkyl, wherein the CO_{2} C_{1-6} alkyl is linear or branched, and

(5) a 5- or 6-membered heterocycle which may be saturated or unsaturated comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being unsubstituted or substituted with 1-3 substituents independently selected from oxo, OH, halogen, C_{1-6} alkyl, and OC_{1-6} alkyl, wherein the C_{1-6} alkyl and OC_{1-6} alkyl are linear or branched and optionally substituted with 1-5 halogens;

R_{8} is C_{1-6} alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 groups independently selected from halogen, CO_{2} H, and CO_{2} C_{1-6} alkyl, wherein the CO_{2} C_{1-6} alkyl is linear or branched;

R_{9} and R_{10} may be the same or different and are hydrogen, straight or branched alkyl of from one to six carbon atoms, lower alkylaryl, lower alkenyl, phenyl, CF_{3}, hydroxy, lower alkoxy, lower alklythio, lower alkylsulphonyl, CF_{3} O, at the six position halogen, nitro, carboxy, lower alkoxy carbonyl, NR_{11} R_{12} CO, NR_{11} R_{12}, R_{11} CONR_{12}, CN, NR_{11} R_{12} SO_{2}, wherein R_{11} and R_{12} may be the same or different and are hydrogen, lower alkyl, or aryl; R_{9} and R_{10} may together form a carbocyclic or methylenedioxy ring;

R_{14} is cyano, cyanomethyl, methoxymethyl, or ethoxymethyl;

X_{2} is O, N(H), or S, het is a 5 or 6-membered heterocycle, n is 0, 1, 2, or 3, and each D is an unbranched lower alkyl group;

U is a substituent selected from halogen atom; cyano; lower alkyl wherein one or more hydrogen atoms on the lower alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carboxamoyl, amino, aryl, and a monocyclic or bicyclic heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms; lower alklythio wherein one or more hydrogen atoms on the alkyl group are
optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl; lower alkylsulfonyl wherein one or more hydrogen atoms on the alkyl group are optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, amino, and aryl; hydroxyl; lower alkoxy; formyl; lower alkylcarbonyl; arylcarbonyl; carboxyl; lower alkoxy carbonyl; carbamoyl; N-lower alkyl carbamoyl; N,N-di-lower alkylaminocarbonyl; amino; N-lower alkyl amino; N,N-di-lower alkyl amino; formyl amino; lower alkyl carbonylamino; aminosulfonylamino; (N-lower alkylamino)sulfonylamino; aryl, optionally substituted by groups selected from a halogen atom, hydroxyl, carbamoyl, aryl and amino; and a monocyclic or bicyclic heterocyclic group containing one or more hetero-atoms selected from nitrogen, oxygen, and sulfur atoms;

W, X, Y, and Z are each, independently, N, S, O, CU or CH, such that at least one of W, X, Y, and Z is N;

A is

\[
\begin{align*}
\text{D is unbranched lower alkyl;} \\
\text{R}_{15} \text{ and } \text{R}_{16} \text{ are each independently substituted or unsubstituted C}_{1}, \text{C}_{2}, \text{C}_{3}, \text{C}_{4}, \text{C}_{5}, \text{C}_{6}, \text{C}_{7}, \text{or } \text{C}_{8}, \text{ straight chain alkyl, or substituted or unsubstituted C}_{3}, \text{C}_{4}, \text{C}_{5}, \text{C}_{6}, \text{C}_{7}, \text{or } \text{C}_{8}, \text{ branched chain alkyl;} \\
\text{L is a single bond or CH}_{2}; \\
\text{m is 0, 1, or 2;} \\
\text{n is 0, 1, 2, 3, or 4;} \\
\text{Y}_{1} \text{ is } -(\text{CH}_{2})_{2} - , -(\text{CH}_{2})_{3} - , -(\text{CH}_{2})_{2} \text{CH(} \text{CH}_{3}- \text{ or } -(\text{CH}_{2})_{2} \text{C(} \text{CH}_{3} 2 \text{ ;} \\
\text{R}_{17} \text{ is aryl or heteroaryl;} \\
\text{R}_{18} \text{ and } \text{R}_{19} \text{ are each independently } \text{C}_{1}-\text{C}_{4} \text{ alkyl or 2-methoxyethyl;} \\
\text{R}_{20} \text{ is hydrogen, } \text{C}_{1}-\text{C}_{4} \text{ alkyl, 2-(C}_{1}-\text{C}_{4} \text{ alkoxy)ethyl, cyclopropylmethyl, benzyl, or } -(\text{CH}_{2})_{m} \text{COR}_{21} \text{ where } m \text{ is 1, 2 or 3 and } R_{21} \text{ is hydroxy, } \text{C}_{1}-\text{C}_{4} \text{ alkoxy or } -\text{NR}_{22} \text{ where } R_{22} \text{ hydrogen or } \text{C}_{1}-\text{C}_{4} \text{ alkyl;}
\end{align*}
\]
R\textsubscript{23} and R\textsubscript{24} can be the same or different and are hydrogen, methyl, or ethyl as well as pharmaceutically acceptable salts thereof.

52. The method of claim 41, the primary amine compound being selected from the group consisting of:

\[
\begin{align*}
\text{NH}_2 \\
\text{C}_6\text{H}_{10} & \quad \text{;}
\end{align*}
\]

\[
\begin{align*}
\text{NH}_2 \\
\text{C}_6\text{H}_{10} & \quad \text{;}
\end{align*}
\]

\[
\begin{align*}
\text{NH}_2 \\
\text{C}_6\text{H}_{10} & \quad \text{;}
\end{align*}
\]

\[
\begin{align*}
\text{NH}_2 \\
\text{C}_6\text{H}_{10} & \quad \text{;}
\end{align*}
\]
and pharmaceutically acceptable salts thereof.

53. The method of claim 41, wherein the primary amine compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
ABSTRACT

A method of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina, the method comprising administering to the subject a therapeutically effective amount of a primary amine compound of formula:

\[ \text{R}_1 \text{NH}_2 \]

wherein \( \text{R}_1 \) is an aliphatic and/or aromatic compound; the primary amine compound upon administration to the subject forming a reversible Schiff-base with the all-trans-retinal or its metabolite including A2E and retinal dimer without adversely affecting normal retinoid cycle performance; the primary amine compound when administered to a Rdh8\(^{-/-}\)Abca4\(^{-/-}\) mouse increasing the optical coherence tomography score of the mouse to at least about 2.5 and increasing 11-cis-retinal amount at least about 30% in comparison to untreated control animal, wherein the primary amine compound is not a local anesthetic, which includes an aromatic amine, that demonstrates sodium channel blockade when administered to the subject.
Fig. 1
Fig. 2
Differential spectrum between unprotonated and protonated Schiff base.

Fig. 3A-B
Differential spectrum between unprotonated and protonated Schiff base.

Fig. 4A-B
Differential spectrum between unprotonated and protonated Schiff base.

Fig. 5
Fig. 7
Grading with OCT

No light

Light

effective

5

↓

1

not effective

score 5

score 4

score 3

→ ELM

score 2

score 1

Fig. 9
# Electronic Acknowledgement Receipt

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>EFS ID</td>
<td>6595568</td>
</tr>
<tr>
<td>Application Number</td>
<td>61267645</td>
</tr>
<tr>
<td>International Application Number</td>
<td></td>
</tr>
<tr>
<td>Confirmation Number</td>
<td>5526</td>
</tr>
<tr>
<td>Title of Invention</td>
<td>METHOD OF TREATING OCULAR DISORDERS</td>
</tr>
<tr>
<td>First Named Inventor/Applicant Name</td>
<td>Krzysztof Palksewski</td>
</tr>
<tr>
<td>Customer Number</td>
<td>68705</td>
</tr>
<tr>
<td>Filer</td>
<td>Richard A. Sutkus/Janet Sherrill</td>
</tr>
<tr>
<td>Filer Authorized By</td>
<td>Richard A. Sutkus</td>
</tr>
<tr>
<td>Attorney Docket Number</td>
<td>CWR-019171US PRO</td>
</tr>
<tr>
<td>Receipt Date</td>
<td>08-DEC-2009</td>
</tr>
<tr>
<td>Filing Date</td>
<td></td>
</tr>
<tr>
<td>Time Stamp</td>
<td>16:16:47</td>
</tr>
<tr>
<td>Application Type</td>
<td>Provisional</td>
</tr>
</tbody>
</table>

## Payment information:

- **Submitted with Payment**: yes
- **Payment Type**: Credit Card
- **Payment was successfully received in RAM**: $110
- **RAM confirmation Number**: 2943
- **Deposit Account**: Authorised User

## File Listing:

<table>
<thead>
<tr>
<th>Document Number</th>
<th>Document Description</th>
<th>File Name</th>
<th>File Size(Bytes)/Message Digest</th>
<th>Multi Part./zip</th>
<th>Pages (if appl.)</th>
</tr>
</thead>
</table>


<table>
<thead>
<tr>
<th></th>
<th>Provisional Cover Sheet (SB16)</th>
<th>TRANSMITTAL.pdf</th>
<th>34474</th>
<th>no</th>
<th>2</th>
</tr>
</thead>
</table>

**Warnings:**
This is not a USPTO supplied Provisional Cover Sheet SB16 form.

**Information:**

|   | PVAPPLICATION.pdf | 602485 | yes | 104 |

**Multipart Description/PDF files in .zip description**

<table>
<thead>
<tr>
<th>Document Description</th>
<th>Start</th>
<th>End</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specification</td>
<td>1</td>
<td>61</td>
</tr>
<tr>
<td>Claims</td>
<td>62</td>
<td>103</td>
</tr>
<tr>
<td>Abstract</td>
<td>104</td>
<td>104</td>
</tr>
</tbody>
</table>

**Warnings:**

|   | Drawings-only black and white line drawings | CWR019171USPRODRAWINGS.pdf | 619844 | no | 9 |

**Information:**

|   | Fee Worksheet (PTO-875) | fee-info.pdf | 29759 | no | 2 |

**Warnings:**

**Information:**

Total Files Size (in bytes): 1286562
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on thisAcknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.